JPS6353970B2 - - Google Patents
Info
- Publication number
- JPS6353970B2 JPS6353970B2 JP56017994A JP1799481A JPS6353970B2 JP S6353970 B2 JPS6353970 B2 JP S6353970B2 JP 56017994 A JP56017994 A JP 56017994A JP 1799481 A JP1799481 A JP 1799481A JP S6353970 B2 JPS6353970 B2 JP S6353970B2
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- antithrombin
- present
- coagulation
- low affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960002897 heparin Drugs 0.000 claims description 144
- 229920000669 heparin Polymers 0.000 claims description 144
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 139
- 239000004019 antithrombin Substances 0.000 claims description 113
- 150000003839 salts Chemical class 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 239000000701 coagulant Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229920002684 Sepharose Polymers 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 description 32
- 238000005345 coagulation Methods 0.000 description 32
- 230000002401 inhibitory effect Effects 0.000 description 29
- 230000023555 blood coagulation Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 208000032843 Hemorrhage Diseases 0.000 description 23
- 208000034158 bleeding Diseases 0.000 description 23
- 230000000740 bleeding effect Effects 0.000 description 23
- 239000008280 blood Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 21
- 229940095529 heparin calcium Drugs 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 108010000499 Thromboplastin Proteins 0.000 description 9
- 102000002262 Thromboplastin Human genes 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 239000003114 blood coagulation factor Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 108010071241 Factor XIIa Proteins 0.000 description 2
- 108010080805 Factor XIa Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 208000010476 Respiratory Paralysis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 239000002565 heparin fraction Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
æ¬çºæã¯ã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³
ãæå¹æåãšããŠå«æããåºè¡ã®å±éºæ§ã®å°ãªã
å®å šãªæè¡æ¶²ååºå€ã«é¢ããã è¡æ¶²ååºã«ã¯çµç¹ããã³ããã©ã¹ãã³ã®é¢äžã«
ããååºããå€å ç³»ååºæ©æ§ããã³è¡äžã®XIIå å
ã掻æ§åãããã€ã±ãè¡äžã®ååºå åã®ã¿ã§åè¡
ãèµ·ããå å ç³»ååºæ©æ§ãããããšã¯ãã§ã«ç¥ã
ãããšãã®ã§ããã å€å ç³»ååºæ©æ§ã®ç¹åŸŽã¯è¡äžã«ååšããªãç©
質ãã€ãŸãçµç¹å åïŒçµç¹ããã³ããã©ã¹ãã³ïŒ
ãè¡äžã®å åã掻æ§åãã掻æ§åããå å
ïŒïœå åïŒãçµç¹ããã³ããã©ã¹ãã³ãšè€åäœ
ã圢æãããããå åã掻æ§åããç¹ã«ããã ãŸãå å ç³»ååºæ©æ§ã®ç¹åŸŽã¯ç©è³ªã®è¡šé¢æ¥è§Šã«
ããXIIå åïŒããŒã²ãã³å åïŒã掻æ§åããã掻
æ§åãããXIIå åïŒXIIïœå åïŒãXIå åã掻æ§å
ãã掻æ§åããXIå åïŒXIïœå åïŒãå åã掻
æ§åãã掻æ§åããå åïŒïœå åïŒãå å
çã®ååã«ããå åã掻æ§åããç¹ã«ããããª
ã掻æ§åããå åïŒïœå åïŒãå åçã®å
åã«ããããããã³ãã³ã掻æ§åãããã以åŸè¡
液ååºã®æçµçŸè±¡ã«è³ãçµè·¯ã¯äž¡æ©æ§ã«ãããŠå ±
éã§ããã ããŠè¿å¹Žã¢ã³ãããã³ãã³ïŒATãšç¥èšã
ããïŒãè¡æ¶²ååºã«ä¿ãçŸæ£ãšã®é¢é£ã«ãããŠæ³š
ç®ãéãã€ã€ãããããã¯ã¢ã³ãããã³ãã³ã
ã»ãšãã©ã®è¡æ¶²ååºå åãé»å®³ããããšãã§ãã
è¡æ¶²ååºåå¿ã®å¶åŸ¡æ©æ§ã«ãããŠéèŠãªå°äœãå
ããŠããããã§ããã ã¢ã³ãããã³ãã³ã¯Î±2âãã¯ãã°ãããªã³ã«
å±ããç³èçœè³ªã§ãããçŽ10ïŒ ã®ç³ãšçµåããäž
æ¬éããªãããããããªããäžåã®ååå ãžã¹ã«
ãã€ãçµåãæãããã¢ããé žçµæã§ã¯å¡©åºæ§ã¢
ããé žç¹ã«ãªãžã³ã®å«éãé«ãã®ãç¹åŸŽã§ããã
ã¢ã³ãããã³ãã³ã¯ã»ãšãã©ã®æŽ»æ§åååºå å
ãé»å®³ããããšãã§ããå ç«åŠçããŒã¿ã«ããã°
ããã³ãã³é»å®³æŽ»æ§ã®75ïŒ ãæ ããšãŸã§èšãã
ããèšåºçã«ãã¢ã³ãããã³ãã³æ¬ ä¹çæ£è ã«
éèè¡æ å¡æ çãå€çºããããšãããã®éèŠæ§ã¯
æçã§ãããã¢ã³ãããã³ãã³æ¬ ä¹çã«ããã
ã¢ã³ãããã³ãã³ã®è¡äžæ¿åºŠã¯æ£åžžã®å Žåã®ã
ããã40ã50ïŒ ãŸã§ããäœäžããªãããã®äºå®ã¯
ã¢ã³ãããã³ãã³ãè¡æ¶²ååºç³»ã«ãããåè¡¡ã«
察ããŠéèŠãªå åã§ãããè¡äžæ¿åºŠãæ£åžžå€ã®40
ã50ïŒ ä»¥äžã«ãªã€ãå Žåã«ã¯èŽæ»çãšãªãããšã
瀺åããŠããã ããŠè¡æŒ¿äžã®ã¢ã³ãããã³ãã³ã«ããé»å®³äœ
çšã¯ååäžã®ã¢ã«ã®ãã³æ®åºãè¡æ¶²ååºç³»ãæ§æ
ããåçš®ã®ã»ãªã³ãããã¢ãŒãŒçŸ€ã®æŽ»æ§ã»ãªã³æ®
åºãšçµåãå®å šãªè€åäœã圢æããŠãããã®é µçŽ
掻æ§ãé»å®³ããããšã«ãããšèšãããããã®è€å
äœåœ¢æã®åå¿é床ã¯ããªãé ããã®ã§ããããå
å¿ç³»ã«ãããªã³ãååšãããšããããªã³ãã¢ã³ã
ããã³ãã³ã«ç¹ç°çã«çµåããŠãã®ç«äœæ§é ã
å€ããã¢ã³ãããã³ãã³ãšã»ãªã³ãããã¢ãŒãŒ
矀ãšã®çµåã300ã500åã«å éããããããªã³ã«
ãããã®åå¿ä¿é²ã¯ã¢ã³ãããã³ãã³ã«ãããŠ
ã®ã¿èªããããç¹ç°ççŸè±¡ã§ãããä»ã®é»å®³å å
ã«ãããŠã¯èªããããªããã€ãŸãããããªã³ã¯ã¢
ã³ãããã³ãã³ãä»ããŠè¡æ¶²ååºç³»ã«éèŠãªå¹
æããããããŠããã®ã§ããã ãšããã§ããããªã³ã®ãã®å¹æã¯ãããªã³ä»¥å€
ã®ä»ã®é žæ§ã ã³å€ç³é¡ã§ã¯ã»ãšãã©ã¿ãããªãã
ãã®äºå®ã¯ãããªã³ã®ã¢ã³ãããã³ãã³æŽ»æ§äº¢
é²å¹æããããªã³ã®ç¡«é žåºã®æ°ãšçš®é¡ããã³ç³æ§
é ãšæ·±ãé¢ä¿ããŠããããšã瀺åããŠããããã
ãããããªã³çæ³ã«ãããŠã¯ãããªã³ã®çŽåºŠãã
ããã¯ãããªã³ã®ååã粟補ãéèŠãªåé¡ãšããŠ
æ®ãããŠããããšãæå³ããŠãããã€ãŸããããª
ã³ãé©åœãªæ¹æ³ã«ããååããå Žåãåååãšã¢
ã³ãããã³ãã³ãšã®é¢ä¿ãããã¯ããã«ååå
ãšè¡æ¶²ååºç³»ãã®ãã®ãšã®çŽæ¥çãªé¢ä¿ãã©ããª
ã€ãŠããããæ確ã«ããå¿ èŠãæ®ãããŠããã®ã§
ããã åŸæ¥ãããªã³çæ³ã®éèŠãªäžé¢ã¯ã¢ã³ãããã³
ãã³ã«ããé»å®³åå¿ã«å¯Ÿãããã®åå¿è§Šåªãšã
ãŠã®æ©èœããããªã³ã«ããã«çºæ®ãããããã«ã
ããšèšãããšãã§ãããšãããŠæ¥ããããããªã
ãããããªã³çæ³ã®çŸç¶ã«ã¯ãããšããšä»¥äžã«ç€º
ãããšãåºæ¬çæ¬ ç¹ããããããã«ã€ããŠã¯æªã
ã«é©åãªã解決ãäžããããŠããªãã®ã§ãããã
ãªãã¡ç¬¬äžã«åè¿°ã®ããšããããªã³ã¯ã¢ã³ããã
ã³ãã³ã«ããé»å®³åå¿ã觊åªãããã®ã§ãã
ãããã®åé¢ã¢ã³ãããã³ãã³èªäœã«å¯ŸãçŽæ¥
çµåããŠéé¢ã¢ã³ãããã³ãã³ã®è¡äžæ¿åºŠãäœ
äžãããããããã¢ã³ãããã³ãã³äœäžçãã
ãããæ¬ ç¹ãããã®ã§ãããåŸæ¥ããäžè¬ã«äœ¿çš
ãããŠããåžè²©ãããªã³ã¯ã¢ã³ãããã³ãã³ã«
察ã匷ã芪åæ§ããããã¢ã³ãããã³ãã³äœäž
çãææ¥ããŠããããã®çµæãååçŸè±¡ãšããŠã®
匷ãåºè¡åŸåãé«ããŠããŸã€ãŠããã®ã§ããã第
äºã«çŸåšäœ¿çšãããŠãããããªã³ã®çŽåºŠã倧ãã
ã°ãã€ããŠããã補åãšããŠéåžžã«äžå質ã§ãã
ãšããæ¬ ç¹ããããããªãã¡åžè²©ãããªã³ã¯ã
ã¿ããããžããŠã·ã®å°è žç²èãã¯ãžã©ã®èºããã³
è žç²èçãå·¥æ¥çè³æºãšããŠããããã補é ãã
ãŠãããã€ã®ãªã¹è¬å±æ¹èŠå®ãããã¯æ¥æ¬è¬å±æ¹
èŠå®ã®æšæºçæ¹æ³ã«ãã掻æ§ã枬å®ãããšè£œåã«
ãã掻æ§ãäžå®ãããããããã®æ瞟ã¯å¿ ããã
in Vivoã§ã®ãããªã³ã®äœçšãåæ ããŠããªããš
ããå ±åãå€ãã®ã§ããã ãããç¶æ³ã«ããããããªã³çæ³ã«ãããæ¹å
ç 究ã¯äž»ãšããŠãããªã³ã粟補ããŠé«çŽåºŠåãé«
åäœåããããšãã€ãŸãããã«ãã€ãŠèšåºçšéã
å¯åçã«å°éã«æãããã®çµæãã¢ã³ãããã³ã
ã³æžå°ççã®åŒå®³ãã§ããã ãæå¶ããããšã«
ããããŠãããšèšãããšãã§ããã äŸãã°ãããŒãŒã³ãã«ã¯çã¯ãããªã³äžã«ã¯ã
ãã®ã¢ã³ãããã³ãã³ã«èŠªåæ§ã®é«ããããªã³
ïŒHigh Affinity HeparinãšåŒã°ããïŒãšå察ã«
芪åæ§ã®äœããããªã³ïŒLow Affinity Heparin
ãšåŒã°ããïŒãšãååŠéè«çã«çŽïŒïŒïŒã®å²åã§
ååšããããšãèŠåºããæåè¡æŽ»æ§ã¯Low
Affinity Heparinã«ã¯ã»ãšãã©ãªããå察ã«
High Affinity Heparinã¯åæãããªã³ããïŒã
ïŒåé«ã掻æ§ã瀺ãããšãå ±åããŠãããã€ãŸ
ããããã«ãããŠã¯High Affinity Heparinãã
ãé«çŽåºŠãé«åäœãããªã³ã§ãããããã䜿çšã
ãã°èšåºçšéãå°ããŠããããã¢ã³ãããã³ãã³
ã®æžå°ãå°ããªãã®ã«æå¶ããããšãã§ããèš
åºäžããããŠæå©ãªçµæããããããšããæ¹åæ¹
åã瀺ãããŠããããšã«ãªãããããçºèŠã«é¢ä¿
ããŠç¹é¡æ52â20164ããããããã«ã¯ãããªã³
ã«ããå¯äœçšã®åå ã¯ãããªã³è£œå€äžã®äžçŽç©ã«
ãããšæãããã®ã§ããããªã³ãåžçå€ïŒè¡æŒ¿è
çœãçµåããæ Œåçµåã¢ã³ãããã³ãã³ïŒãçšã
ãŠç²Ÿè£œããé«æ¯æŽ»æ§åããæè¡ãé瀺ãããŠãã
ã®ã§ããã ããŠãæ¬çºæè ã¯ãããåŸæ¥æè¡ããµãŸããŠã
ãã«ãããªã³çæ³ã«ã€ãç 究ãè¡ã€ãçµæã以äž
ã«ç€ºãããšãæ°äºå®ãèŠåºãã«è³ã€ãã ããªãã¡ãããŒãŒã³ãã«ã¯çãLow Affinity
HeparinãšåŒã³ããããªã³æŽ»æ§ãã»ãŒçç¡ã§ãã
ãšãããã®ã«å¯Ÿå¿ããŠãæ¬çºæè ã¯åŸã«å®çŸ©ãã
ããšãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ãªã
ç©è³ªãååŸããããã®ç©è³ªã¯ã¢ã³ãããã³ãã³
ã«å¯ŸããŠèŠªåæ§ãäœã以å€ã«ãåŸèšå®éšäŸïŒãïŒ
ã®å®éšã®çµæãå€å ç³»ååºã«å¯ŸããŠã»ãšãã©é»å®³
掻æ§ã瀺ãããå察ã«å å ç³»ååºã«å¯ŸããŠããç¹
ç°çã«é»å®³æŽ»æ§ã瀺ãç©è³ªã§ããããšãå€æã
ãã ããªãã¡ã以äž(1)ã(3)ã®ç¹åŸŽã«èŠçŽãããã (1) ã¢ã³ãããã³ãã³ã«å¯ŸããŠèŠªåæ§ãäœã (2) å€å ç³»ååºã«å¯ŸããŠã»ãšãã©é»å®³æŽ»æ§ããªã (3) å å ç³»ååºã«å¯ŸããŠããç¹ç°çã«é»å®³æŽ»æ§ã
ãã åŸæ¥ããã®åžè²©ãããªã³ã¯åºè¡åŸåãæããé·
æçæ³ã«ãããŠã¯ã¢ã³ãããã³ãã³æžå°ã«ãã
è¡æ åŸåãææ¥ããããããã«ãæ¬çºæè ã®ã¢ã³
ãããã³ãã³äœèŠªåæ§ãããªã³ã¯ãåèšäžã€ã®
ç¹åŸŽããèããŠãé·æçæ³ã«ãããŠã¢ã³ãããã³
ãã³æžå°ã«ããè¡æ åŸåãææ¥ããããšããª
ãããŸãå¯äœçšãšããŠã®åºè¡åŸåã匱ããããã
ååãªãæè¡æ¶²ååºäœçšã瀺ãè¬å€ãšãªãå¯èœæ§
ãæšå®ããããäºå®ãåŸèšå®éšäŸïŒã«ãã€ãŠæ¬çº
æã¯åºè¡åŸåã®åŒ±ãå®å šãªæè¡æ¶²ååºå€ã§ããã
ãšã蚌æãããã åèšç¹åŸŽã®ãã¡(3)ã®äºå®ã¯æ¬çºæè ããŸã€ãã
æ°ãã«èŠåºãããã®ã§ãããæ¬çºæã¯ãããç¥èŠ
ã«ããšã¥ããŠå®æããããã®ã§ããã 次ã«åŸèšå®éšäŸãšã®é¢é£ã«ãããŠæ¬çºæããã
ã«è©³çŽ°ã«èª¬æããã ïœ ååœè¬å±æ¹ã«èŠå®ããããããªã³æŽ»æ§ã®æž¬å®
æ³ã¯äž»ãšããŠå€å ç³»ååºã«ãããé»å®³æŽ»æ§ã枬
å®ããŠãããã®ã§ããã äŸãã°æ¥æ¬è¬å±æ¹ç¬¬ä¹çããããªã³ãããªãŠ
ã ãã®å®éæ³ã®é ã«ã¯ãããªã³ãããã³ããã
ãŒãŒæœåºæ¶²ããã³è¡æ¶²ãæ··åããŠååºæéã枬
å®ãã趣æšã®æž¬å®æ¹æ³ãèšèŒãããŠãããçµ
å±ãå€å ç³»ååºã«ãããé»å®³æŽ»æ§ããã€ãŠãã
ãªã³æŽ»æ§ãå®ããŠããã®ã§ãããïŒåæ²¢åäœç£
ä¿®ããããªã³ãè¬è«ç€Ÿçºè¡134é åç §ïŒ ãšããã§åŸèšå®éšäŸïŒã«ç€ºãããããšããæ¬
çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããª
ã³ã¯æ¥æ¬è¬å±æ¹èŠå®ã®æ¹æ³ã«æºããæ¹æ³ã«ãã€
ãŠãããªã³æŽ»æ§ã枬å®ãããšãããã»ãŒçç¡ã§
ãã€ããåŸã€ãŠåœè©²ãããªã³ã¯å€å ç³»ååºã«å¯Ÿ
ãã»ãšãã©é»å®³æŽ»æ§ãæããªãããšãå€æãã
åèšç¹åŸŽ(2)ã確èªãããã ïœ æ¬¡ã«å€å ç³»ååºå åãè² è·ããããã€ã±ãæ¥
觊å åã«ãã€ãŠã®ã¿ååºããç³»ãããªãã¡å å
ç³»ååºã®ã¿ãã€ãããããã«ãããªã³ãå ããŠ
å šè¡ååºæéïŒWhole Blood Clotting TimeïŒ
ã枬å®ããå Žåããã®ååºæéã«å»¶é·ãèªãã
ããã°ãããã¯å å ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ã®
ååšã蚌æãããã®ãšãªããããªãã¡ããããª
ã³ã¯è¡æŒ¿äžã®ã¢ã³ãããã³ãã³ãšååããŠXII
ïœãXIïœãïœãïœã®åå åããã³ããã³ã
ã³ãé»å®³ããããšãããã€ãŠããã®ã§ãåŸèšå®
éšäŸïŒã«ç€ºãããããšãå€å ç³»ååºå åãè² è·
ãããããšããªãããã«ããŠãããªã³ãå ãå š
è¡ååºæéã枬å®ãããã®æéã«é 延ãèªãã
ããã°ããã®é 延ã¯ãããªã³ã®å å ç³»ååºé»å®³
ã«ãããã®ã§ããããšãããããããã§ãåŸèš
å®éšäŸïŒã®çµæãå ·äœçã«è¿°ã¹ãã°ä»¥äžã®ããš
ãã§ãã€ããã€ãŸãéåžžã®å šè¡ååºæéãïŒå
ã«å»¶é·ããããã«èŠããéãªããå䟡ããã€ãŠ
æ¯èŒããå Žåãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³ã¯ãã¢ã³ãããã³ãã³é«
芪åæ§ãããªã³ïŒã¢ã³ãããã³ãã³ã«å¯Ÿã芪
åæ§ã®é«ããããªã³ã§ãããæ¬çºæã«é¢é£ããŠ
åŸã«å®çŸ©ããïŒãããã¯ãããªã³ã«ã«ã·ãŠã
ïŒåååããã«ãªã³ãšããŠäžè¬ã«å ¥æãåŸãåž
販ãããªã³å€ïŒã«ãããå¿ èŠåäœéã®1/5ã§ã
ãããšãå€æããã®ã§ãããæèšããã°ãæ¬çº
æã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³
ã¯å å ç³»ååºã«å¯ŸããŠç¹ç°çã«é»å®³æŽ»æ§ã瀺
ãããã®æŽ»æ§ã®åŒ·ãã¯ã¢ã³ãããã³ãã³é«èŠª
åæ§ãããªã³ãããã¯ãããªã³ã«ã«ã·ãŠã ã®ïŒ
åã§ããããšãå€æããã®ã§ãã€ãŠãåèšç¹åŸŽ
(3)ã確èªãããã ïœ ããã«ãæ¬çºæè ã¯å å ç³»ååºã«å¯Ÿããé»å®³
äœçšã®æç¶æ§ã«ã€ããŠæ€èšãããã€ãŸãå å ç³»
ååºã«å¯Ÿããé»å®³æŽ»æ§ãããã«é«ããã®ã§ãã€
ãŠãããã®æŽ»æ§äœçšã«æç¶æ§ããªãå Žåã«ã¯æ
è¡æ¶²ååºå€ãšããŠã®æºè¶³ãã¹ãå¹æãçºæ®ãã
ããšãã§ããªãã®ã¯åœç¶ã§ãããããã§å®éšäŸ
ïŒã«ç€ºãããããšããæ¬çºæã«ä¿ãã¢ã³ããã
ãã³äœèŠªåæ§ãããªã³ããã³ã¢ã³ãããã³ã
ã³é«èŠªåæ§ãããªãªã³ããã³ãããªã³ã«ã«ã·
ãŠã ã®äžè ã«ã€ããŠãå å ç³»ååºã«å¯Ÿããé»å®³
掻æ§ãåäžã«æããŠïŒããªãã¡äœèŠªåæ§ãããª
ã³ã®ã¿ä»ã®1/5åäœéã«ããŠïŒæäžããäžå®æ
éåŸã«ãããå¹æïŒå šè¡ååºæéïŒãæ¯èŒãã
ãšãããåäžã®çµæãäžãããåŸã€ãŠãå å ç³»
ååºã«å¯Ÿããæè¡æ¶²ååºäœçšã®æç¶æ§ã«ãããŠ
äžè ã¯åäžã§ããããšãå€æããã ïœ ãããªã³ã®æã倧ããªå¯äœçšã¯åºè¡ãææ¥
ããåºè¡æéã延é·ããããšã§ãã€ãŠãå€å ç³»
ååºã«å¯Ÿããé»å®³æŽ»æ§ã®åŒ·ããšåºè¡ã®å±éºæ§ãš
ãçžé¢ããããšã¯äžè¬ã«ããç¥ããããšããã§
ããããšããã§ãæ¬çºæã«ä¿ãã¢ã³ãããã³ã
ã³äœèŠªåæ§ãããªã³ã¯åèšã®ããšãã¢ã³ãã
ãã³ãã³é«èŠªåæ§ãããªã³ããã³ãããªã³ã«
ã«ã·ãŠã ã«æ¯èŒããŠå å ç³»ååºã«å¯Ÿãããéžæ
çã«é»å®³æŽ»æ§ã瀺ããå å ç³»ååºã«å¯Ÿãåäžã®
é»å®³å¹æãªãã³ã«åäžã®é»å®³äœçšæç¶æ§ãäžã
ãããã«å¿ èŠãªéã¯ãæ¬çºæã«ä¿ãã¢ã³ããã
ã³ãã³äœèŠªåæ§ãããªã³ã«ãããŠã¯ä»ã®äºã€
ã®ãããªã³ã«æ¯èŒããŠ1/5ã®åäœéã§ãããã
ã®äºå®ã¯ãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœ
芪åæ§ãããªã³ãåºè¡ã®å±éºæ§ã®å°ãªãå®å šãª
æè¡æ¶²ååºå€ãšãªãå¯èœæ§ã瀺åããŠããã ãããå®èšŒããããã«æ¬çºæã¯å®éšäŸïŒã«ã
ããŠç€ºãããšããæäžåŸã«ãããåºè¡æé
ïŒBleeding TimeïŒã®å»¶é·ãæ¯èŒããããã®çµ
ææ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³ã¯ä»ã®äºã€ã®ãããªã³ã«æ¯èŒããŠåºè¡æ
éã®å»¶é·ãå°ãããåŸã€ãŠãåºè¡ã®å±éºæ§ã®å°
ãããã®ã§ããããšãå€æããã ïœ ãŸãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªå
æ§ãããªã³ã®æ¥æ§æ¯æ§ã«ã€ããŠè©Šéšãããšãã
éèæäžã«ãããLD50ã¯1000mgïŒKg以äžã§ã
ã€ããæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªå
æ§ãããªã³ãšã¯çäœã®çççPHããã³çççå¡©
æ¿åºŠã«ãããŠã¢ã³ãããã³ãã³ã«å¯Ÿã芪åæ§
ã®äœããããªã³ãæå³ããããå®éã®ç©è³ªãšã
ãŠã¯äŸãã°ä»¥äžã«ç€ºãããšãå ·äœç補æ³ããã€
ãŠç¹å®ããããšãã§ããã ããªãã¡ããŸããã¢ã³ãããã³ãã³ãã»ã
ã¢ããŒãºã®ããšãæ Œåã«çµåããããŠæ Œåçµå
ã¢ã³ãããã³ãã³ãšãããããããªãã¢ãã€
ããã€ãŒã¯ãããã«ã©ã ãã€ããã次ã«ããã«
åŸæ¥ããäžè¬ã«äœ¿çšãããŠæ¥ãåžè²©ãããªã³ã
è² è·ããçççPHããã³çççå¡©æ¿åºŠã«ããã
ã¢ãã€ããã€ãŒã¯ãããããããªãã ãã®ã¯ãããã°ã©ãã€ãŒæäœã«ãããŠãæ Œå
çµåã¢ã³ãããã³ãã³ã«åžçãããã«æº¶åºã
ãŠæ¥ããããªã³ãååšãããªãã°ããã®ãããª
ã³ãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§
ãããªã³ãšç§°ããããšãã§ããã ããã«æ Œåãšã¯äŸãã°ã»ãã¢ããŒãº4Bçã
èšãããæ¬çºæã¯ããã«éå®ãããªãã æ Œåçµåã¢ã³ãããã³ãã³ãšã¯ããããã
è¡æŒ¿ãããšãåºããã¢ã³ãããã³ãã³ãæ Œå
ã«çµåãããããã®ã§ãããå ·äœçã«ã¯äŸãã°
以äžã®ããšãã«ããŠèª¿è£œãããã ã¢ã³ãããã³ãã³200mgã0.2MâNaHCO3
ïŒPH9.0ïŒ200mlã«æº¶è§£ãããããããã ã·ã¢ã³æŽ»
æ§åã»ãã¢ããŒãºCLâ4Bã²ã«ã«å ããŠæžæ¿ãã
ïŒâã§24æéãããæ¹æãããéãã0.2Mâ
NaHCO3ïŒPH9.0ïŒã§æ°åæŽæµããæçµçã«ã¯
0.2MâNaHCO3ïŒPH9.0ïŒã«æžæ¿ããã çççPHãšã¯PHïŒãïŒã®ç¯å²ã®PHãæå³ãããŸ
ãçççå¡©æ¿åºŠãšã¯å¡©åãããªãŠã æ¿åºŠã«æç®ã
ãŠ0.05Mã0.20ã®ç¯å²ã®æ¿åºŠãæå³ãããåŸã€ãŠ
äŸãã°0.05Mããªã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ã0.05Mã
0.20M NaclïŒã䜿çšããã°æå®ã®æ¡ä»¶ãæºãã
ããšãã§ããããããæ¬çºæã¯åœè©²ããªã¹å¡©é žç·©
è¡æ¶²ã«éå®ããããã®ã§ã¯ãªããããã«èŠå®ãã
çççPHããã³çççå¡©æ¿åºŠãæºãããã®ã§ãã
ã°ãã¥ãã§ãããã æ¬çºæã«ãããŠã¢ã³ãããã³ãã³é«èŠªåæ§ã
ããªã³ãšã¯æ¬çºæã«ä¿ãã¢ã³ããããã³äœèŠªå
æ§ãããªã³ã«å¯Ÿç«ããæ šå¿µã®ãã®ã§ãããçäœã®
çççPHããã³çççå¡©æ¿åºŠã«ãããŠã¢ã³ããã
ã³ãã³ã«å¯Ÿã芪åæ§ã®é«ããããªã³ãæå³ã
ããåŸã€ãŠäŸãã°äžã€ã®å ·äœçãªè£œæ³ããã€ãŠç¹
å®ãããªãã°ãæ¬çºæã«ãããŠèŠå®ããçççPH
ããã³çççå¡©æ¿åºŠã«ãããŠæ Œåçµåã¢ã³ããã
ã³ãã³åžçãããããªã³ã¯ã¢ã³ãããã³ãã³
é«èŠªåæ§ãããªã³ã®äžçš®ã§ãããšå®çŸ©ããããšã
ã§ããããã®ã¢ã³ãããã³ãã³é«èŠªåæ§ãããª
ã³ã¯ãçççPHããã³çççå¡©æ¿åºŠã«ãããŠæ Œå
çµåã¢ã³ãããã³ãã³ã«ãã€ããåžçãããã
åŸã次ã«PHã®ã¿ãçççPHã«ä¿æããå¡©æ¿åºŠãç
ççå¡©æ¿åºŠä»¥äžã®å¡©æ¿ã«ããŠã¢ãã€ããã€ãŒã¯ã
ãããè¡ãã°æ Œåçµåã¢ã³ãããã³ãã³ããè±
çããããããšãã§ããã¢ã³ãããã³ãã³äœèŠª
åæ§ãããªã³ããåé¢ããŠååŸããããšãã§ã
ãã æ¬çºæã®æè¡æ¶²ååºå€ã®å ·äœçãªå€åã¯æ³šå°å€
ã§ãããé泚åã¯ç®äžæ³šã«ãã€ãŠæäžãããããŸ
ãäžæ¥ã®æäžéã¯10åäœïŒJPåäœïŒã5000åäœ
ïŒJPåäœïŒïŒäººãé©åœã§ããããæ¬çºæã¯ããã«
éå®ãããªãã 以äžã«èšèŒããå®éšäŸã¯æ¬çºæã®å¹æãããã«
詳现ã«èª¬æãããã®ã§ããã å®éšäŸ ïŒ ïŒ è©Š æ ãããªã³ã«ã«ã·ãŠã æ¬çºæã«ãããã¢ã³ãããã³ãã³é«èŠªåæ§
ãããªã³ æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³ ïŒ å®éšåç© äœé3.0ã3.6Kgã®éæ§çœè²åšæ¥çš®ãŠãµã®ãçš
ãã宀枩21ã24âã®åç©å®€ã«ãããŠãŠãµã®çšåº
å飌æORCâïŒïŒãªãªãšã³ã¿ã«é µæ¯ç€Ÿè£œïŒãæ¯
æ¥100ïœãã€äžããæ°Žéæ°Žãèªç±ã«æåãããŠã
ïŒã±æ以äžé£Œè²ãããã®ãå®éšã«äŸããã ïŒ å®éšæ¹æ³ ãããªã³åäœ æ¥æ¬è¬å±æ¹ã«æºããŠãå€å ç³»åè¡é»æ¢æŽ»æ§ã«
ãããããªã³åäœã®æ€å®ãè¡ã€ãã (a) æšæºæ¶²ã®èª¿è£œ åäœæ¢ç¥ã®ãããªã³æº¶æ¶²ãïŒïŒ ã°ã«ã³ãŒã¹
溶液ã§åžéããŠ8.53ÎŒïŒmlïŒé«æ¿åºŠæšæºæº¶æ¶²
SHïŒããã³6.83ÎŒïŒmlïŒäœæ¿åºŠæšæºæº¶æ¶²SLïŒ
ããããã調補ããã (b) è©Šæ溶液ã®èª¿è£œ ãããªã³ã«ã«ã·ãŠã 10.1mgãæ¬çºæã«ãã
ãã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³6.6
mgããã³æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœ
芪åæ§ãããªã³9.5mgã粟秀ããããããã
ïŒïŒ ã°ã«ã³ãŒã¹æ¶²ã§200mlã400mlã20mlã«æº¶
解ããããããã®é«æ¿åºŠè©Šæ液T1HãT2Hã
T3Hã調補ããããã«ãããã®é«æ¿åºŠè©Šæ
液ïŒmlãïŒïŒ ã°ã«ã³ãŒã¹æ¶²ã§10mlã«åžéãã
ããããã®äœæ¿åºŠè©Šæ液T1LãT2LãT3Lã
調補ããã (c) è¡ æŒ¿ ãããããïŒmlã®3.13ïŒ ã¯ãšã³é žãããªãŠ
ã 液ãå ¥ãã10mlã®ãã©ã¹ããã¯è£œæ³šå°åš
ïŒãã«ã¢ã·ãªã³ãžïŒã§ãŠãµã®è³éèããïŒml
ã®è¡æ¶²ãæ¡åããæ··ååŸãçŽã¡ã«3000r.p.m
ã§10åéé å¿ããŠè¡æŒ¿ãåé¢ããïŒã10âã®
å·æã«ä¿åããå®éšã«äŸããã (d) çµç¹ããã³ããã©ã¹ãã³æ¶²ã®èª¿è£œ åžè²©ã®ããã³ããã©ã¹ãã³è©Šè¬ïŒã·ã³ãã©
ã¹ãã³ïŒãŠãµã®è³ããã³èºã®ããã³ããã©
ã¹ãã³ïŒãçšãã20testçšãã€ã¢ã«å ¥ããã
ã³ããã©ã¹ãã³ãïŒmlã®èžçæ°Žã§æº¶è§£ããŠå®
éšã«äŸããã (e) æäœæ³ ããããã³ãã³æé枬å®çšã®ãã€ããã¡ãŒ
ã¿ãŒïŒBaltimor Biological Laboratory補ïŒ
ãçšããŠèªåçãã€å®¢èŠ³çã«è¡ã€ããããªã
ã¡ããã€ããã¡ãŒã¿ãŒã®ã»ã«ã«SHãSLã
THããã³TLãå¥ã ã«0.1mlãã€å ¥ãããã
ã«ããããã«è¡æŒ¿0.1mlãå ãã次ã«ããã³
ããã©ã¹ãã³æ¶²0.1mlãå ãããšåæã«èªå
çã«ãã€ããã¡ãŒã¿ãŒãäœåãããååºæé
ã枬å®ããã ïŒ çµ æ çµæãè¡šïŒã«ç€ºãããªãããã®æç©ã«ããšã¥
ããŠæ¥æ¬è¬å±èŠå®ã®æ€å®æ³ã«åŸãå䟡ïŒJPå
äœïŒãç®åºãããšä»¥äžã®ããšãã§ãã€ãã ãããªã³ã«ã«ã·ãŠã 200ÎŒïŒmg æ¬çºæã«ãããã¢ã³ãããã³ãã³é«èŠªåæ§ ãããªã³ 390ÎŒïŒmg æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ ãããªã³ 3ÎŒïŒmg
ãæå¹æåãšããŠå«æããåºè¡ã®å±éºæ§ã®å°ãªã
å®å šãªæè¡æ¶²ååºå€ã«é¢ããã è¡æ¶²ååºã«ã¯çµç¹ããã³ããã©ã¹ãã³ã®é¢äžã«
ããååºããå€å ç³»ååºæ©æ§ããã³è¡äžã®XIIå å
ã掻æ§åãããã€ã±ãè¡äžã®ååºå åã®ã¿ã§åè¡
ãèµ·ããå å ç³»ååºæ©æ§ãããããšã¯ãã§ã«ç¥ã
ãããšãã®ã§ããã å€å ç³»ååºæ©æ§ã®ç¹åŸŽã¯è¡äžã«ååšããªãç©
質ãã€ãŸãçµç¹å åïŒçµç¹ããã³ããã©ã¹ãã³ïŒ
ãè¡äžã®å åã掻æ§åãã掻æ§åããå å
ïŒïœå åïŒãçµç¹ããã³ããã©ã¹ãã³ãšè€åäœ
ã圢æãããããå åã掻æ§åããç¹ã«ããã ãŸãå å ç³»ååºæ©æ§ã®ç¹åŸŽã¯ç©è³ªã®è¡šé¢æ¥è§Šã«
ããXIIå åïŒããŒã²ãã³å åïŒã掻æ§åããã掻
æ§åãããXIIå åïŒXIIïœå åïŒãXIå åã掻æ§å
ãã掻æ§åããXIå åïŒXIïœå åïŒãå åã掻
æ§åãã掻æ§åããå åïŒïœå åïŒãå å
çã®ååã«ããå åã掻æ§åããç¹ã«ããããª
ã掻æ§åããå åïŒïœå åïŒãå åçã®å
åã«ããããããã³ãã³ã掻æ§åãããã以åŸè¡
液ååºã®æçµçŸè±¡ã«è³ãçµè·¯ã¯äž¡æ©æ§ã«ãããŠå ±
éã§ããã ããŠè¿å¹Žã¢ã³ãããã³ãã³ïŒATãšç¥èšã
ããïŒãè¡æ¶²ååºã«ä¿ãçŸæ£ãšã®é¢é£ã«ãããŠæ³š
ç®ãéãã€ã€ãããããã¯ã¢ã³ãããã³ãã³ã
ã»ãšãã©ã®è¡æ¶²ååºå åãé»å®³ããããšãã§ãã
è¡æ¶²ååºåå¿ã®å¶åŸ¡æ©æ§ã«ãããŠéèŠãªå°äœãå
ããŠããããã§ããã ã¢ã³ãããã³ãã³ã¯Î±2âãã¯ãã°ãããªã³ã«
å±ããç³èçœè³ªã§ãããçŽ10ïŒ ã®ç³ãšçµåããäž
æ¬éããªãããããããªããäžåã®ååå ãžã¹ã«
ãã€ãçµåãæãããã¢ããé žçµæã§ã¯å¡©åºæ§ã¢
ããé žç¹ã«ãªãžã³ã®å«éãé«ãã®ãç¹åŸŽã§ããã
ã¢ã³ãããã³ãã³ã¯ã»ãšãã©ã®æŽ»æ§åååºå å
ãé»å®³ããããšãã§ããå ç«åŠçããŒã¿ã«ããã°
ããã³ãã³é»å®³æŽ»æ§ã®75ïŒ ãæ ããšãŸã§èšãã
ããèšåºçã«ãã¢ã³ãããã³ãã³æ¬ ä¹çæ£è ã«
éèè¡æ å¡æ çãå€çºããããšãããã®éèŠæ§ã¯
æçã§ãããã¢ã³ãããã³ãã³æ¬ ä¹çã«ããã
ã¢ã³ãããã³ãã³ã®è¡äžæ¿åºŠã¯æ£åžžã®å Žåã®ã
ããã40ã50ïŒ ãŸã§ããäœäžããªãããã®äºå®ã¯
ã¢ã³ãããã³ãã³ãè¡æ¶²ååºç³»ã«ãããåè¡¡ã«
察ããŠéèŠãªå åã§ãããè¡äžæ¿åºŠãæ£åžžå€ã®40
ã50ïŒ ä»¥äžã«ãªã€ãå Žåã«ã¯èŽæ»çãšãªãããšã
瀺åããŠããã ããŠè¡æŒ¿äžã®ã¢ã³ãããã³ãã³ã«ããé»å®³äœ
çšã¯ååäžã®ã¢ã«ã®ãã³æ®åºãè¡æ¶²ååºç³»ãæ§æ
ããåçš®ã®ã»ãªã³ãããã¢ãŒãŒçŸ€ã®æŽ»æ§ã»ãªã³æ®
åºãšçµåãå®å šãªè€åäœã圢æããŠãããã®é µçŽ
掻æ§ãé»å®³ããããšã«ãããšèšãããããã®è€å
äœåœ¢æã®åå¿é床ã¯ããªãé ããã®ã§ããããå
å¿ç³»ã«ãããªã³ãååšãããšããããªã³ãã¢ã³ã
ããã³ãã³ã«ç¹ç°çã«çµåããŠãã®ç«äœæ§é ã
å€ããã¢ã³ãããã³ãã³ãšã»ãªã³ãããã¢ãŒãŒ
矀ãšã®çµåã300ã500åã«å éããããããªã³ã«
ãããã®åå¿ä¿é²ã¯ã¢ã³ãããã³ãã³ã«ãããŠ
ã®ã¿èªããããç¹ç°ççŸè±¡ã§ãããä»ã®é»å®³å å
ã«ãããŠã¯èªããããªããã€ãŸãããããªã³ã¯ã¢
ã³ãããã³ãã³ãä»ããŠè¡æ¶²ååºç³»ã«éèŠãªå¹
æããããããŠããã®ã§ããã ãšããã§ããããªã³ã®ãã®å¹æã¯ãããªã³ä»¥å€
ã®ä»ã®é žæ§ã ã³å€ç³é¡ã§ã¯ã»ãšãã©ã¿ãããªãã
ãã®äºå®ã¯ãããªã³ã®ã¢ã³ãããã³ãã³æŽ»æ§äº¢
é²å¹æããããªã³ã®ç¡«é žåºã®æ°ãšçš®é¡ããã³ç³æ§
é ãšæ·±ãé¢ä¿ããŠããããšã瀺åããŠããããã
ãããããªã³çæ³ã«ãããŠã¯ãããªã³ã®çŽåºŠãã
ããã¯ãããªã³ã®ååã粟補ãéèŠãªåé¡ãšããŠ
æ®ãããŠããããšãæå³ããŠãããã€ãŸããããª
ã³ãé©åœãªæ¹æ³ã«ããååããå Žåãåååãšã¢
ã³ãããã³ãã³ãšã®é¢ä¿ãããã¯ããã«ååå
ãšè¡æ¶²ååºç³»ãã®ãã®ãšã®çŽæ¥çãªé¢ä¿ãã©ããª
ã€ãŠããããæ確ã«ããå¿ èŠãæ®ãããŠããã®ã§
ããã åŸæ¥ãããªã³çæ³ã®éèŠãªäžé¢ã¯ã¢ã³ãããã³
ãã³ã«ããé»å®³åå¿ã«å¯Ÿãããã®åå¿è§Šåªãšã
ãŠã®æ©èœããããªã³ã«ããã«çºæ®ãããããã«ã
ããšèšãããšãã§ãããšãããŠæ¥ããããããªã
ãããããªã³çæ³ã®çŸç¶ã«ã¯ãããšããšä»¥äžã«ç€º
ãããšãåºæ¬çæ¬ ç¹ããããããã«ã€ããŠã¯æªã
ã«é©åãªã解決ãäžããããŠããªãã®ã§ãããã
ãªãã¡ç¬¬äžã«åè¿°ã®ããšããããªã³ã¯ã¢ã³ããã
ã³ãã³ã«ããé»å®³åå¿ã觊åªãããã®ã§ãã
ãããã®åé¢ã¢ã³ãããã³ãã³èªäœã«å¯ŸãçŽæ¥
çµåããŠéé¢ã¢ã³ãããã³ãã³ã®è¡äžæ¿åºŠãäœ
äžãããããããã¢ã³ãããã³ãã³äœäžçãã
ãããæ¬ ç¹ãããã®ã§ãããåŸæ¥ããäžè¬ã«äœ¿çš
ãããŠããåžè²©ãããªã³ã¯ã¢ã³ãããã³ãã³ã«
察ã匷ã芪åæ§ããããã¢ã³ãããã³ãã³äœäž
çãææ¥ããŠããããã®çµæãååçŸè±¡ãšããŠã®
匷ãåºè¡åŸåãé«ããŠããŸã€ãŠããã®ã§ããã第
äºã«çŸåšäœ¿çšãããŠãããããªã³ã®çŽåºŠã倧ãã
ã°ãã€ããŠããã補åãšããŠéåžžã«äžå質ã§ãã
ãšããæ¬ ç¹ããããããªãã¡åžè²©ãããªã³ã¯ã
ã¿ããããžããŠã·ã®å°è žç²èãã¯ãžã©ã®èºããã³
è žç²èçãå·¥æ¥çè³æºãšããŠããããã補é ãã
ãŠãããã€ã®ãªã¹è¬å±æ¹èŠå®ãããã¯æ¥æ¬è¬å±æ¹
èŠå®ã®æšæºçæ¹æ³ã«ãã掻æ§ã枬å®ãããšè£œåã«
ãã掻æ§ãäžå®ãããããããã®æ瞟ã¯å¿ ããã
in Vivoã§ã®ãããªã³ã®äœçšãåæ ããŠããªããš
ããå ±åãå€ãã®ã§ããã ãããç¶æ³ã«ããããããªã³çæ³ã«ãããæ¹å
ç 究ã¯äž»ãšããŠãããªã³ã粟補ããŠé«çŽåºŠåãé«
åäœåããããšãã€ãŸãããã«ãã€ãŠèšåºçšéã
å¯åçã«å°éã«æãããã®çµæãã¢ã³ãããã³ã
ã³æžå°ççã®åŒå®³ãã§ããã ãæå¶ããããšã«
ããããŠãããšèšãããšãã§ããã äŸãã°ãããŒãŒã³ãã«ã¯çã¯ãããªã³äžã«ã¯ã
ãã®ã¢ã³ãããã³ãã³ã«èŠªåæ§ã®é«ããããªã³
ïŒHigh Affinity HeparinãšåŒã°ããïŒãšå察ã«
芪åæ§ã®äœããããªã³ïŒLow Affinity Heparin
ãšåŒã°ããïŒãšãååŠéè«çã«çŽïŒïŒïŒã®å²åã§
ååšããããšãèŠåºããæåè¡æŽ»æ§ã¯Low
Affinity Heparinã«ã¯ã»ãšãã©ãªããå察ã«
High Affinity Heparinã¯åæãããªã³ããïŒã
ïŒåé«ã掻æ§ã瀺ãããšãå ±åããŠãããã€ãŸ
ããããã«ãããŠã¯High Affinity Heparinãã
ãé«çŽåºŠãé«åäœãããªã³ã§ãããããã䜿çšã
ãã°èšåºçšéãå°ããŠããããã¢ã³ãããã³ãã³
ã®æžå°ãå°ããªãã®ã«æå¶ããããšãã§ããèš
åºäžããããŠæå©ãªçµæããããããšããæ¹åæ¹
åã瀺ãããŠããããšã«ãªãããããçºèŠã«é¢ä¿
ããŠç¹é¡æ52â20164ããããããã«ã¯ãããªã³
ã«ããå¯äœçšã®åå ã¯ãããªã³è£œå€äžã®äžçŽç©ã«
ãããšæãããã®ã§ããããªã³ãåžçå€ïŒè¡æŒ¿è
çœãçµåããæ Œåçµåã¢ã³ãããã³ãã³ïŒãçšã
ãŠç²Ÿè£œããé«æ¯æŽ»æ§åããæè¡ãé瀺ãããŠãã
ã®ã§ããã ããŠãæ¬çºæè ã¯ãããåŸæ¥æè¡ããµãŸããŠã
ãã«ãããªã³çæ³ã«ã€ãç 究ãè¡ã€ãçµæã以äž
ã«ç€ºãããšãæ°äºå®ãèŠåºãã«è³ã€ãã ããªãã¡ãããŒãŒã³ãã«ã¯çãLow Affinity
HeparinãšåŒã³ããããªã³æŽ»æ§ãã»ãŒçç¡ã§ãã
ãšãããã®ã«å¯Ÿå¿ããŠãæ¬çºæè ã¯åŸã«å®çŸ©ãã
ããšãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ãªã
ç©è³ªãååŸããããã®ç©è³ªã¯ã¢ã³ãããã³ãã³
ã«å¯ŸããŠèŠªåæ§ãäœã以å€ã«ãåŸèšå®éšäŸïŒãïŒ
ã®å®éšã®çµæãå€å ç³»ååºã«å¯ŸããŠã»ãšãã©é»å®³
掻æ§ã瀺ãããå察ã«å å ç³»ååºã«å¯ŸããŠããç¹
ç°çã«é»å®³æŽ»æ§ã瀺ãç©è³ªã§ããããšãå€æã
ãã ããªãã¡ã以äž(1)ã(3)ã®ç¹åŸŽã«èŠçŽãããã (1) ã¢ã³ãããã³ãã³ã«å¯ŸããŠèŠªåæ§ãäœã (2) å€å ç³»ååºã«å¯ŸããŠã»ãšãã©é»å®³æŽ»æ§ããªã (3) å å ç³»ååºã«å¯ŸããŠããç¹ç°çã«é»å®³æŽ»æ§ã
ãã åŸæ¥ããã®åžè²©ãããªã³ã¯åºè¡åŸåãæããé·
æçæ³ã«ãããŠã¯ã¢ã³ãããã³ãã³æžå°ã«ãã
è¡æ åŸåãææ¥ããããããã«ãæ¬çºæè ã®ã¢ã³
ãããã³ãã³äœèŠªåæ§ãããªã³ã¯ãåèšäžã€ã®
ç¹åŸŽããèããŠãé·æçæ³ã«ãããŠã¢ã³ãããã³
ãã³æžå°ã«ããè¡æ åŸåãææ¥ããããšããª
ãããŸãå¯äœçšãšããŠã®åºè¡åŸåã匱ããããã
ååãªãæè¡æ¶²ååºäœçšã瀺ãè¬å€ãšãªãå¯èœæ§
ãæšå®ããããäºå®ãåŸèšå®éšäŸïŒã«ãã€ãŠæ¬çº
æã¯åºè¡åŸåã®åŒ±ãå®å šãªæè¡æ¶²ååºå€ã§ããã
ãšã蚌æãããã åèšç¹åŸŽã®ãã¡(3)ã®äºå®ã¯æ¬çºæè ããŸã€ãã
æ°ãã«èŠåºãããã®ã§ãããæ¬çºæã¯ãããç¥èŠ
ã«ããšã¥ããŠå®æããããã®ã§ããã 次ã«åŸèšå®éšäŸãšã®é¢é£ã«ãããŠæ¬çºæããã
ã«è©³çŽ°ã«èª¬æããã ïœ ååœè¬å±æ¹ã«èŠå®ããããããªã³æŽ»æ§ã®æž¬å®
æ³ã¯äž»ãšããŠå€å ç³»ååºã«ãããé»å®³æŽ»æ§ã枬
å®ããŠãããã®ã§ããã äŸãã°æ¥æ¬è¬å±æ¹ç¬¬ä¹çããããªã³ãããªãŠ
ã ãã®å®éæ³ã®é ã«ã¯ãããªã³ãããã³ããã
ãŒãŒæœåºæ¶²ããã³è¡æ¶²ãæ··åããŠååºæéã枬
å®ãã趣æšã®æž¬å®æ¹æ³ãèšèŒãããŠãããçµ
å±ãå€å ç³»ååºã«ãããé»å®³æŽ»æ§ããã€ãŠãã
ãªã³æŽ»æ§ãå®ããŠããã®ã§ãããïŒåæ²¢åäœç£
ä¿®ããããªã³ãè¬è«ç€Ÿçºè¡134é åç §ïŒ ãšããã§åŸèšå®éšäŸïŒã«ç€ºãããããšããæ¬
çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããª
ã³ã¯æ¥æ¬è¬å±æ¹èŠå®ã®æ¹æ³ã«æºããæ¹æ³ã«ãã€
ãŠãããªã³æŽ»æ§ã枬å®ãããšãããã»ãŒçç¡ã§
ãã€ããåŸã€ãŠåœè©²ãããªã³ã¯å€å ç³»ååºã«å¯Ÿ
ãã»ãšãã©é»å®³æŽ»æ§ãæããªãããšãå€æãã
åèšç¹åŸŽ(2)ã確èªãããã ïœ æ¬¡ã«å€å ç³»ååºå åãè² è·ããããã€ã±ãæ¥
觊å åã«ãã€ãŠã®ã¿ååºããç³»ãããªãã¡å å
ç³»ååºã®ã¿ãã€ãããããã«ãããªã³ãå ããŠ
å šè¡ååºæéïŒWhole Blood Clotting TimeïŒ
ã枬å®ããå Žåããã®ååºæéã«å»¶é·ãèªãã
ããã°ãããã¯å å ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ã®
ååšã蚌æãããã®ãšãªããããªãã¡ããããª
ã³ã¯è¡æŒ¿äžã®ã¢ã³ãããã³ãã³ãšååããŠXII
ïœãXIïœãïœãïœã®åå åããã³ããã³ã
ã³ãé»å®³ããããšãããã€ãŠããã®ã§ãåŸèšå®
éšäŸïŒã«ç€ºãããããšãå€å ç³»ååºå åãè² è·
ãããããšããªãããã«ããŠãããªã³ãå ãå š
è¡ååºæéã枬å®ãããã®æéã«é 延ãèªãã
ããã°ããã®é 延ã¯ãããªã³ã®å å ç³»ååºé»å®³
ã«ãããã®ã§ããããšãããããããã§ãåŸèš
å®éšäŸïŒã®çµæãå ·äœçã«è¿°ã¹ãã°ä»¥äžã®ããš
ãã§ãã€ããã€ãŸãéåžžã®å šè¡ååºæéãïŒå
ã«å»¶é·ããããã«èŠããéãªããå䟡ããã€ãŠ
æ¯èŒããå Žåãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³ã¯ãã¢ã³ãããã³ãã³é«
芪åæ§ãããªã³ïŒã¢ã³ãããã³ãã³ã«å¯Ÿã芪
åæ§ã®é«ããããªã³ã§ãããæ¬çºæã«é¢é£ããŠ
åŸã«å®çŸ©ããïŒãããã¯ãããªã³ã«ã«ã·ãŠã
ïŒåååããã«ãªã³ãšããŠäžè¬ã«å ¥æãåŸãåž
販ãããªã³å€ïŒã«ãããå¿ èŠåäœéã®1/5ã§ã
ãããšãå€æããã®ã§ãããæèšããã°ãæ¬çº
æã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³
ã¯å å ç³»ååºã«å¯ŸããŠç¹ç°çã«é»å®³æŽ»æ§ã瀺
ãããã®æŽ»æ§ã®åŒ·ãã¯ã¢ã³ãããã³ãã³é«èŠª
åæ§ãããªã³ãããã¯ãããªã³ã«ã«ã·ãŠã ã®ïŒ
åã§ããããšãå€æããã®ã§ãã€ãŠãåèšç¹åŸŽ
(3)ã確èªãããã ïœ ããã«ãæ¬çºæè ã¯å å ç³»ååºã«å¯Ÿããé»å®³
äœçšã®æç¶æ§ã«ã€ããŠæ€èšãããã€ãŸãå å ç³»
ååºã«å¯Ÿããé»å®³æŽ»æ§ãããã«é«ããã®ã§ãã€
ãŠãããã®æŽ»æ§äœçšã«æç¶æ§ããªãå Žåã«ã¯æ
è¡æ¶²ååºå€ãšããŠã®æºè¶³ãã¹ãå¹æãçºæ®ãã
ããšãã§ããªãã®ã¯åœç¶ã§ãããããã§å®éšäŸ
ïŒã«ç€ºãããããšããæ¬çºæã«ä¿ãã¢ã³ããã
ãã³äœèŠªåæ§ãããªã³ããã³ã¢ã³ãããã³ã
ã³é«èŠªåæ§ãããªãªã³ããã³ãããªã³ã«ã«ã·
ãŠã ã®äžè ã«ã€ããŠãå å ç³»ååºã«å¯Ÿããé»å®³
掻æ§ãåäžã«æããŠïŒããªãã¡äœèŠªåæ§ãããª
ã³ã®ã¿ä»ã®1/5åäœéã«ããŠïŒæäžããäžå®æ
éåŸã«ãããå¹æïŒå šè¡ååºæéïŒãæ¯èŒãã
ãšãããåäžã®çµæãäžãããåŸã€ãŠãå å ç³»
ååºã«å¯Ÿããæè¡æ¶²ååºäœçšã®æç¶æ§ã«ãããŠ
äžè ã¯åäžã§ããããšãå€æããã ïœ ãããªã³ã®æã倧ããªå¯äœçšã¯åºè¡ãææ¥
ããåºè¡æéã延é·ããããšã§ãã€ãŠãå€å ç³»
ååºã«å¯Ÿããé»å®³æŽ»æ§ã®åŒ·ããšåºè¡ã®å±éºæ§ãš
ãçžé¢ããããšã¯äžè¬ã«ããç¥ããããšããã§
ããããšããã§ãæ¬çºæã«ä¿ãã¢ã³ãããã³ã
ã³äœèŠªåæ§ãããªã³ã¯åèšã®ããšãã¢ã³ãã
ãã³ãã³é«èŠªåæ§ãããªã³ããã³ãããªã³ã«
ã«ã·ãŠã ã«æ¯èŒããŠå å ç³»ååºã«å¯Ÿãããéžæ
çã«é»å®³æŽ»æ§ã瀺ããå å ç³»ååºã«å¯Ÿãåäžã®
é»å®³å¹æãªãã³ã«åäžã®é»å®³äœçšæç¶æ§ãäžã
ãããã«å¿ èŠãªéã¯ãæ¬çºæã«ä¿ãã¢ã³ããã
ã³ãã³äœèŠªåæ§ãããªã³ã«ãããŠã¯ä»ã®äºã€
ã®ãããªã³ã«æ¯èŒããŠ1/5ã®åäœéã§ãããã
ã®äºå®ã¯ãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœ
芪åæ§ãããªã³ãåºè¡ã®å±éºæ§ã®å°ãªãå®å šãª
æè¡æ¶²ååºå€ãšãªãå¯èœæ§ã瀺åããŠããã ãããå®èšŒããããã«æ¬çºæã¯å®éšäŸïŒã«ã
ããŠç€ºãããšããæäžåŸã«ãããåºè¡æé
ïŒBleeding TimeïŒã®å»¶é·ãæ¯èŒããããã®çµ
ææ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³ã¯ä»ã®äºã€ã®ãããªã³ã«æ¯èŒããŠåºè¡æ
éã®å»¶é·ãå°ãããåŸã€ãŠãåºè¡ã®å±éºæ§ã®å°
ãããã®ã§ããããšãå€æããã ïœ ãŸãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªå
æ§ãããªã³ã®æ¥æ§æ¯æ§ã«ã€ããŠè©Šéšãããšãã
éèæäžã«ãããLD50ã¯1000mgïŒKg以äžã§ã
ã€ããæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªå
æ§ãããªã³ãšã¯çäœã®çççPHããã³çççå¡©
æ¿åºŠã«ãããŠã¢ã³ãããã³ãã³ã«å¯Ÿã芪åæ§
ã®äœããããªã³ãæå³ããããå®éã®ç©è³ªãšã
ãŠã¯äŸãã°ä»¥äžã«ç€ºãããšãå ·äœç補æ³ããã€
ãŠç¹å®ããããšãã§ããã ããªãã¡ããŸããã¢ã³ãããã³ãã³ãã»ã
ã¢ããŒãºã®ããšãæ Œåã«çµåããããŠæ Œåçµå
ã¢ã³ãããã³ãã³ãšãããããããªãã¢ãã€
ããã€ãŒã¯ãããã«ã©ã ãã€ããã次ã«ããã«
åŸæ¥ããäžè¬ã«äœ¿çšãããŠæ¥ãåžè²©ãããªã³ã
è² è·ããçççPHããã³çççå¡©æ¿åºŠã«ããã
ã¢ãã€ããã€ãŒã¯ãããããããªãã ãã®ã¯ãããã°ã©ãã€ãŒæäœã«ãããŠãæ Œå
çµåã¢ã³ãããã³ãã³ã«åžçãããã«æº¶åºã
ãŠæ¥ããããªã³ãååšãããªãã°ããã®ãããª
ã³ãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§
ãããªã³ãšç§°ããããšãã§ããã ããã«æ Œåãšã¯äŸãã°ã»ãã¢ããŒãº4Bçã
èšãããæ¬çºæã¯ããã«éå®ãããªãã æ Œåçµåã¢ã³ãããã³ãã³ãšã¯ããããã
è¡æŒ¿ãããšãåºããã¢ã³ãããã³ãã³ãæ Œå
ã«çµåãããããã®ã§ãããå ·äœçã«ã¯äŸãã°
以äžã®ããšãã«ããŠèª¿è£œãããã ã¢ã³ãããã³ãã³200mgã0.2MâNaHCO3
ïŒPH9.0ïŒ200mlã«æº¶è§£ãããããããã ã·ã¢ã³æŽ»
æ§åã»ãã¢ããŒãºCLâ4Bã²ã«ã«å ããŠæžæ¿ãã
ïŒâã§24æéãããæ¹æãããéãã0.2Mâ
NaHCO3ïŒPH9.0ïŒã§æ°åæŽæµããæçµçã«ã¯
0.2MâNaHCO3ïŒPH9.0ïŒã«æžæ¿ããã çççPHãšã¯PHïŒãïŒã®ç¯å²ã®PHãæå³ãããŸ
ãçççå¡©æ¿åºŠãšã¯å¡©åãããªãŠã æ¿åºŠã«æç®ã
ãŠ0.05Mã0.20ã®ç¯å²ã®æ¿åºŠãæå³ãããåŸã€ãŠ
äŸãã°0.05Mããªã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ã0.05Mã
0.20M NaclïŒã䜿çšããã°æå®ã®æ¡ä»¶ãæºãã
ããšãã§ããããããæ¬çºæã¯åœè©²ããªã¹å¡©é žç·©
è¡æ¶²ã«éå®ããããã®ã§ã¯ãªããããã«èŠå®ãã
çççPHããã³çççå¡©æ¿åºŠãæºãããã®ã§ãã
ã°ãã¥ãã§ãããã æ¬çºæã«ãããŠã¢ã³ãããã³ãã³é«èŠªåæ§ã
ããªã³ãšã¯æ¬çºæã«ä¿ãã¢ã³ããããã³äœèŠªå
æ§ãããªã³ã«å¯Ÿç«ããæ šå¿µã®ãã®ã§ãããçäœã®
çççPHããã³çççå¡©æ¿åºŠã«ãããŠã¢ã³ããã
ã³ãã³ã«å¯Ÿã芪åæ§ã®é«ããããªã³ãæå³ã
ããåŸã€ãŠäŸãã°äžã€ã®å ·äœçãªè£œæ³ããã€ãŠç¹
å®ãããªãã°ãæ¬çºæã«ãããŠèŠå®ããçççPH
ããã³çççå¡©æ¿åºŠã«ãããŠæ Œåçµåã¢ã³ããã
ã³ãã³åžçãããããªã³ã¯ã¢ã³ãããã³ãã³
é«èŠªåæ§ãããªã³ã®äžçš®ã§ãããšå®çŸ©ããããšã
ã§ããããã®ã¢ã³ãããã³ãã³é«èŠªåæ§ãããª
ã³ã¯ãçççPHããã³çççå¡©æ¿åºŠã«ãããŠæ Œå
çµåã¢ã³ãããã³ãã³ã«ãã€ããåžçãããã
åŸã次ã«PHã®ã¿ãçççPHã«ä¿æããå¡©æ¿åºŠãç
ççå¡©æ¿åºŠä»¥äžã®å¡©æ¿ã«ããŠã¢ãã€ããã€ãŒã¯ã
ãããè¡ãã°æ Œåçµåã¢ã³ãããã³ãã³ããè±
çããããããšãã§ããã¢ã³ãããã³ãã³äœèŠª
åæ§ãããªã³ããåé¢ããŠååŸããããšãã§ã
ãã æ¬çºæã®æè¡æ¶²ååºå€ã®å ·äœçãªå€åã¯æ³šå°å€
ã§ãããé泚åã¯ç®äžæ³šã«ãã€ãŠæäžãããããŸ
ãäžæ¥ã®æäžéã¯10åäœïŒJPåäœïŒã5000åäœ
ïŒJPåäœïŒïŒäººãé©åœã§ããããæ¬çºæã¯ããã«
éå®ãããªãã 以äžã«èšèŒããå®éšäŸã¯æ¬çºæã®å¹æãããã«
詳现ã«èª¬æãããã®ã§ããã å®éšäŸ ïŒ ïŒ è©Š æ ãããªã³ã«ã«ã·ãŠã æ¬çºæã«ãããã¢ã³ãããã³ãã³é«èŠªåæ§
ãããªã³ æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³ ïŒ å®éšåç© äœé3.0ã3.6Kgã®éæ§çœè²åšæ¥çš®ãŠãµã®ãçš
ãã宀枩21ã24âã®åç©å®€ã«ãããŠãŠãµã®çšåº
å飌æORCâïŒïŒãªãªãšã³ã¿ã«é µæ¯ç€Ÿè£œïŒãæ¯
æ¥100ïœãã€äžããæ°Žéæ°Žãèªç±ã«æåãããŠã
ïŒã±æ以äžé£Œè²ãããã®ãå®éšã«äŸããã ïŒ å®éšæ¹æ³ ãããªã³åäœ æ¥æ¬è¬å±æ¹ã«æºããŠãå€å ç³»åè¡é»æ¢æŽ»æ§ã«
ãããããªã³åäœã®æ€å®ãè¡ã€ãã (a) æšæºæ¶²ã®èª¿è£œ åäœæ¢ç¥ã®ãããªã³æº¶æ¶²ãïŒïŒ ã°ã«ã³ãŒã¹
溶液ã§åžéããŠ8.53ÎŒïŒmlïŒé«æ¿åºŠæšæºæº¶æ¶²
SHïŒããã³6.83ÎŒïŒmlïŒäœæ¿åºŠæšæºæº¶æ¶²SLïŒ
ããããã調補ããã (b) è©Šæ溶液ã®èª¿è£œ ãããªã³ã«ã«ã·ãŠã 10.1mgãæ¬çºæã«ãã
ãã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³6.6
mgããã³æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœ
芪åæ§ãããªã³9.5mgã粟秀ããããããã
ïŒïŒ ã°ã«ã³ãŒã¹æ¶²ã§200mlã400mlã20mlã«æº¶
解ããããããã®é«æ¿åºŠè©Šæ液T1HãT2Hã
T3Hã調補ããããã«ãããã®é«æ¿åºŠè©Šæ
液ïŒmlãïŒïŒ ã°ã«ã³ãŒã¹æ¶²ã§10mlã«åžéãã
ããããã®äœæ¿åºŠè©Šæ液T1LãT2LãT3Lã
調補ããã (c) è¡ æŒ¿ ãããããïŒmlã®3.13ïŒ ã¯ãšã³é žãããªãŠ
ã 液ãå ¥ãã10mlã®ãã©ã¹ããã¯è£œæ³šå°åš
ïŒãã«ã¢ã·ãªã³ãžïŒã§ãŠãµã®è³éèããïŒml
ã®è¡æ¶²ãæ¡åããæ··ååŸãçŽã¡ã«3000r.p.m
ã§10åéé å¿ããŠè¡æŒ¿ãåé¢ããïŒã10âã®
å·æã«ä¿åããå®éšã«äŸããã (d) çµç¹ããã³ããã©ã¹ãã³æ¶²ã®èª¿è£œ åžè²©ã®ããã³ããã©ã¹ãã³è©Šè¬ïŒã·ã³ãã©
ã¹ãã³ïŒãŠãµã®è³ããã³èºã®ããã³ããã©
ã¹ãã³ïŒãçšãã20testçšãã€ã¢ã«å ¥ããã
ã³ããã©ã¹ãã³ãïŒmlã®èžçæ°Žã§æº¶è§£ããŠå®
éšã«äŸããã (e) æäœæ³ ããããã³ãã³æé枬å®çšã®ãã€ããã¡ãŒ
ã¿ãŒïŒBaltimor Biological Laboratory補ïŒ
ãçšããŠèªåçãã€å®¢èŠ³çã«è¡ã€ããããªã
ã¡ããã€ããã¡ãŒã¿ãŒã®ã»ã«ã«SHãSLã
THããã³TLãå¥ã ã«0.1mlãã€å ¥ãããã
ã«ããããã«è¡æŒ¿0.1mlãå ãã次ã«ããã³
ããã©ã¹ãã³æ¶²0.1mlãå ãããšåæã«èªå
çã«ãã€ããã¡ãŒã¿ãŒãäœåãããååºæé
ã枬å®ããã ïŒ çµ æ çµæãè¡šïŒã«ç€ºãããªãããã®æç©ã«ããšã¥
ããŠæ¥æ¬è¬å±èŠå®ã®æ€å®æ³ã«åŸãå䟡ïŒJPå
äœïŒãç®åºãããšä»¥äžã®ããšãã§ãã€ãã ãããªã³ã«ã«ã·ãŠã 200ÎŒïŒmg æ¬çºæã«ãããã¢ã³ãããã³ãã³é«èŠªåæ§ ãããªã³ 390ÎŒïŒmg æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ ãããªã³ 3ÎŒïŒmg
ãè¡šã
åèšããããšããæ¥æ¬è¬å±æ¹èŠå®ã®æ¹æ³ã«ãã
枬å®ããããããªã³ã®å䟡ã¯äž»ãšããŠå€å ç³»ååº
ã«å¯Ÿããé»å®³æŽ»æ§ããã€ãŠè¡šç€ºããããã®ã§ã
ããåŸã€ãŠãæ¬å®éšäŸã«ãããŠç®åºãããäžèšå
䟡ããå€æããã°æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³ã¯å€å ç³»ååºã«å¯ŸããŠã»ãšã
ã©é»å®³æŽ»æ§ãæããªãããšãå€æããã å®éšäŸ ïŒ å®éšäŸïŒã§çšããããããã®è©Šæ溶液ãïŒïŒ ã°
ã«ã³ãŒã¹æ¶²ã§åžéããŠ0.8ÎŒïŒmlã0.4ÎŒïŒmlã
0.2ÎŒïŒmlã0.1ÎŒïŒmlã0.05ÎŒïŒmlã®æ¿åºŠã«èª¿è£œãã
ãããã0.1mlã泚å°åšã«å ¥ãããŠãµã®ã®è³éè
ããè¡æ¶²1.9mlãæ¡åããŠæ··åããå šè¡ååºæé
ãLeeâWhiteæ³ã§æž¬å®ããã çµæãè¡šïŒã«ç€ºãã
枬å®ããããããªã³ã®å䟡ã¯äž»ãšããŠå€å ç³»ååº
ã«å¯Ÿããé»å®³æŽ»æ§ããã€ãŠè¡šç€ºããããã®ã§ã
ããåŸã€ãŠãæ¬å®éšäŸã«ãããŠç®åºãããäžèšå
䟡ããå€æããã°æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³ã¯å€å ç³»ååºã«å¯ŸããŠã»ãšã
ã©é»å®³æŽ»æ§ãæããªãããšãå€æããã å®éšäŸ ïŒ å®éšäŸïŒã§çšããããããã®è©Šæ溶液ãïŒïŒ ã°
ã«ã³ãŒã¹æ¶²ã§åžéããŠ0.8ÎŒïŒmlã0.4ÎŒïŒmlã
0.2ÎŒïŒmlã0.1ÎŒïŒmlã0.05ÎŒïŒmlã®æ¿åºŠã«èª¿è£œãã
ãããã0.1mlã泚å°åšã«å ¥ãããŠãµã®ã®è³éè
ããè¡æ¶²1.9mlãæ¡åããŠæ··åããå šè¡ååºæé
ãLeeâWhiteæ³ã§æž¬å®ããã çµæãè¡šïŒã«ç€ºãã
ãè¡šã
ãªãè©Šææ¬äžïŒ¬ã¯æ¬çºæã«ä¿ãã¢ã³ãããã³ã
ã³äœèŠªåæ§ãããªã³ãã¯æ¬çºæã«ãããã¢ã³
ãããã³ãã³é«èŠªåæ§ãããªã³ãHcã¯ãããª
ã³ã«ã«ã·ãŠã ãã³ã³ãããŒã«ã¯ïŒïŒ âã°ã«ã³ãŒã¹
ãããããæå³ããã è¡šïŒãããŠãµã®è¡ã«ãããéåžžã®å šè¡ååºæé
ã¯10ã13åã®ç¯å²ã§ãããæ倧13åã§ããããã
ã§ãã®å šè¡ååºæéããããªã³æäžã®å¹æãšããŠ
ïŒåã«å»¶é·ãããããããªãã¡æ倧26åçšåºŠã«ãŸ
ã§å»¶é·ããããã«èŠãããããªã³æ¿åºŠãå æ¿æ³ã«
ãã€ãŠæ±ããŠã¿ããšãæ¬çºæã«ä¿ãã¢ã³ãããã³
ãã³äœèŠªåæ§ãããªã³ã§ã¯0.0035ÎŒïŒmlãæ¬çº
æã«ãããã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³
ã§ã¯0.0190ÎŒïŒmlãŸããããªã³ã«ã«ã·ãŠã ã§ã¯
0.0160ÎŒïŒmlã§ããã ãšããã§ãæ¬å®éšäŸã«ãããå šè¡ååºæéã¯ã
å€å ç³»ååºå åãè² è·ããããšãªã枬å®ãããã
ã®ã§ãããããåœè©²ååºæéã«ããã延é·ã¯å å
ç³»ååºã«å¯Ÿãããããªã³ã®é»å®³äœçšã«ãã€ãŠãã
ãããããã®ã§ããã åŸã€ãŠãéåžžã®å šè¡ååºæéãïŒåã«å»¶é·ãã
ããã«èŠããæ¿åºŠããã€ãŠæŽ»æ§ã®åŒ·ããæ¯èŒãã
ãªãã°ãå å ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ã«ãããŠã
æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããª
ã³ã¯ãæ¬çºæã«ãããã¢ã³ãããã³ãã³é«èŠªå
æ§ãããªã³ã«å¯Ÿã5.4åãŸããããªã³ã«ã«ã·ãŠã
ã«å¯Ÿã4.6åã§ããããã¥ãã«ãããçŽïŒåçšåºŠ
匷ãããšãå€æããã å®éšäŸ ïŒ ïŒ è©Šæããã³æäžé æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³ïŒ3ÎŒïŒmgãJPåäœïŒæ¬çºæã«ãããã¢
ã³ãããã³ãã³é«èŠªåæ§ãããªã³ïŒ390ÎŒïŒ
mgãJPåäœïŒããã³ãããªã³ã«ã«ã·ãŠã
ïŒ200ÎŒïŒmgãJPåäœïŒãè©Šæãšããããªãå®éš
äŸïŒã®æ瞟ãããã¢ã³ãããã³ãã³äœèŠªåæ§
ãããªã³ã¯ä»ã®äºã€ã®ãããªã³ã«æ¯èŒããŠå å
ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ãïŒå匷ãããšãèªã
ãããŠããã®ã§æ¬å®éšäŸã«ãããŠã¢ã³ãããã³
ãã³äœèŠªåæ§ãããªã³ã®ã¿ä»ã®äºã€ã®ãããª
ã³ã®1/5åäœéããªãã¡20ÎŒïŒJPåäœïŒïŒKgãæ
äžããã ïŒ å®éšåç© äœé2.8ã3.6Kgã®éæ§çœè²åæ¥çš®ãŠãµã®ãçš
ãã宀枩21ã25âã®åç©å®€ã«ãããŠãŠãµã®çšåº
å飌æORCâïŒïŒãªãªãšã³ã¿ã«é µæ¯ç€Ÿè£œïŒãæ¯
æ¥100ïœãã€äžããæ°Žéæ°Žãèªç±ã«æåãããŠã
ïŒã±æ以äžé£Œè²ãããã®ãå®éšã«äŸããã ïŒ è¬ç©æäžãšæ¡è¡æ¡ä»¶ æå®ã®æäžéããŠãµã®ã®å·ŠåŽè³éèã«æäž
ãã15ã30ã60ã120ååŸã«å³åŽè³éèããè¡
液ïŒmlãæ¡åããããªãæè¬çŽåã«ãåæ§ã«è¡
液ãæ¡åããå®éšã®å¯Ÿç §ãšãããæ¡è¡ã«èŠãã
æéã¯ãã¹ãŠïŒå以å ã§ãã€ãã ïŒ åè¡æŽ»æ§æž¬å®æ³ LeeâWhiteæ³ã«ããå šè¡ååºæéã枬å®ã
ããããªãã¡ã2.5ml容éã®ãã©ã¹ããã¯è£œæ³š
å°åšïŒä»äž¹ãã«ã¢ç€Ÿè£œïŒã§è³éèããïŒmlã®è¡
液ãæ¡åããçŽã¡ã«ã¹ããããŠãªãããçºå
ããæ¡åããè¡æ¶²ãéããã«å°è©Šéšç®¡ïŒå åŸïŒ
mmãé·ã10cmïŒïŒæ¬ã«ïŒmlãã€å泚ããŠ37âã®
æž©æ°Žäžã«é眮ããæ¡è¡ïŒååŸããïŒæ¬ã®è©Šéšç®¡
ãïŒåæ¯ã«æã«åããŠã¿ãŠããã¯ãæµåããªã
ãªã€ãæç¹ããããïŒæ¬ã®è©Šéšç®¡ãåæ§ã«åã
ãªããåè¡ã芳å¯ãããæ¡è¡ãã第ïŒã®è©Šéšç®¡
ã®åè¡å®äºãŸã§ã®æéãå šè¡ååºæéãšããã ãŠãµã®ã®å šè¡ååºæéã®æ£åžžå€ã¯ãæ£åžžãŠãµ
ã®12å¹ã®æž¬å®å€ã®99ïŒ ãå ¥ãç¯å²ïŒå¹³åå€Â±
3ÏïŒãšãããšã6.5ã12.5åã§ãã€ãã ïŒ çµ æ çµæãå³ïŒã«ç€ºãã å³ïŒããå å ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ãæã
ãŠæäžãããæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³ãæ¬çºæã«ãããã¢ã³ããã
ã³ãã³é«èŠªåæ§ãããªã³ããã³ãããªã³ã«ã«
ã·ãŠã ã¯åœè©²æŽ»æ§ã®æç¶äœçšã«ã€ããŠåäžã®æ
åã瀺ãããšãå€æããã å®éšäŸ ïŒ ïŒ è©Š æ æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³ïŒ3ÎŒïŒmgãJPåäœïŒãæ¬çºæã«ãããã¢
ã³ãããã³ãã³é«èŠªåæ§ãããªã³ïŒ390ÎŒïŒ
mgãJPåäœïŒããã³ãããªã³ã«ã«ã·ãŠã
ïŒ200ÎŒïŒmgãJPåäœïŒãè©Šæãšããã ïŒ å®éšåç© SDç³»éæ§ã©ããïŒS.P.EïŒãäœé230ã280ïœ ïŒ å®éšæ¹æ³ æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³20ÎŒïŒKgããã³100ÎŒïŒKgãæ¬çºæã«ãã
ãã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³
100ÎŒïŒKgããã³500ÎŒïŒKgããããªã³ã«ã«ã·ãŠ
ã 100ÎŒïŒKgããã³500ÎŒïŒKgãã©ããå°Ÿéèã
ãé泚ãããæè¬æ¶²éããã³æè¬é床ã¯ããã
ã0.1mlïŒ100ïœãçŽ10ç§ïŒ0.1mlã§ããããªã
å¯Ÿç §ãšããŠã¯ïŒïŒ glucose泚å°æ¶²ãæäžããã åºè¡æéã¯Clifftonãã®æ¹æ³ã«æºããŠæž¬å®ã
ããããªãã¡ãã©ããããã©ã¹ããã¯è£œåºå®ç®±
ã«å ¥ãç¡éº»é ç¶æ ã§ãããªã³æäž15ååŸã«å°Ÿã®
å 端ããïŒcmã®éšäœã®å³åŽéèãã¡ã¹ãçšããŠ
åæããçŽãåå£ã«åœãŠè¡æ¶²ãä»çãããåŠ
ãã«ãã€ãŠåºè¡æéã枬å®ããããªãåºè¡ã®æ¿
ããæã¯çŽïŒåæ¯ã«ãããŠæ¢è¡ãããã«ãªã€ãŠ
ããã¯ïŒåæ¯ã«çŽãåå£ã«åœãŠãã ïŒ çµ æ æäž15ååŸã«ãããåºè¡æéã®æž¬å®çµæãè¡š
ïŒã«ç€ºãããªãè¡šïŒã«ã¯ãŠãµã®ã§ã®ãããªã³æ
äž15ååŸã«ãããå šè¡ååºæéã«ã€ããŠã®å®éš
äŸïŒã®å®éšçµæãåèãšããŠä»èšããã
ã³äœèŠªåæ§ãããªã³ãã¯æ¬çºæã«ãããã¢ã³
ãããã³ãã³é«èŠªåæ§ãããªã³ãHcã¯ãããª
ã³ã«ã«ã·ãŠã ãã³ã³ãããŒã«ã¯ïŒïŒ âã°ã«ã³ãŒã¹
ãããããæå³ããã è¡šïŒãããŠãµã®è¡ã«ãããéåžžã®å šè¡ååºæé
ã¯10ã13åã®ç¯å²ã§ãããæ倧13åã§ããããã
ã§ãã®å šè¡ååºæéããããªã³æäžã®å¹æãšããŠ
ïŒåã«å»¶é·ãããããããªãã¡æ倧26åçšåºŠã«ãŸ
ã§å»¶é·ããããã«èŠãããããªã³æ¿åºŠãå æ¿æ³ã«
ãã€ãŠæ±ããŠã¿ããšãæ¬çºæã«ä¿ãã¢ã³ãããã³
ãã³äœèŠªåæ§ãããªã³ã§ã¯0.0035ÎŒïŒmlãæ¬çº
æã«ãããã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³
ã§ã¯0.0190ÎŒïŒmlãŸããããªã³ã«ã«ã·ãŠã ã§ã¯
0.0160ÎŒïŒmlã§ããã ãšããã§ãæ¬å®éšäŸã«ãããå šè¡ååºæéã¯ã
å€å ç³»ååºå åãè² è·ããããšãªã枬å®ãããã
ã®ã§ãããããåœè©²ååºæéã«ããã延é·ã¯å å
ç³»ååºã«å¯Ÿãããããªã³ã®é»å®³äœçšã«ãã€ãŠãã
ãããããã®ã§ããã åŸã€ãŠãéåžžã®å šè¡ååºæéãïŒåã«å»¶é·ãã
ããã«èŠããæ¿åºŠããã€ãŠæŽ»æ§ã®åŒ·ããæ¯èŒãã
ãªãã°ãå å ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ã«ãããŠã
æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããª
ã³ã¯ãæ¬çºæã«ãããã¢ã³ãããã³ãã³é«èŠªå
æ§ãããªã³ã«å¯Ÿã5.4åãŸããããªã³ã«ã«ã·ãŠã
ã«å¯Ÿã4.6åã§ããããã¥ãã«ãããçŽïŒåçšåºŠ
匷ãããšãå€æããã å®éšäŸ ïŒ ïŒ è©Šæããã³æäžé æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³ïŒ3ÎŒïŒmgãJPåäœïŒæ¬çºæã«ãããã¢
ã³ãããã³ãã³é«èŠªåæ§ãããªã³ïŒ390ÎŒïŒ
mgãJPåäœïŒããã³ãããªã³ã«ã«ã·ãŠã
ïŒ200ÎŒïŒmgãJPåäœïŒãè©Šæãšããããªãå®éš
äŸïŒã®æ瞟ãããã¢ã³ãããã³ãã³äœèŠªåæ§
ãããªã³ã¯ä»ã®äºã€ã®ãããªã³ã«æ¯èŒããŠå å
ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ãïŒå匷ãããšãèªã
ãããŠããã®ã§æ¬å®éšäŸã«ãããŠã¢ã³ãããã³
ãã³äœèŠªåæ§ãããªã³ã®ã¿ä»ã®äºã€ã®ãããª
ã³ã®1/5åäœéããªãã¡20ÎŒïŒJPåäœïŒïŒKgãæ
äžããã ïŒ å®éšåç© äœé2.8ã3.6Kgã®éæ§çœè²åæ¥çš®ãŠãµã®ãçš
ãã宀枩21ã25âã®åç©å®€ã«ãããŠãŠãµã®çšåº
å飌æORCâïŒïŒãªãªãšã³ã¿ã«é µæ¯ç€Ÿè£œïŒãæ¯
æ¥100ïœãã€äžããæ°Žéæ°Žãèªç±ã«æåãããŠã
ïŒã±æ以äžé£Œè²ãããã®ãå®éšã«äŸããã ïŒ è¬ç©æäžãšæ¡è¡æ¡ä»¶ æå®ã®æäžéããŠãµã®ã®å·ŠåŽè³éèã«æäž
ãã15ã30ã60ã120ååŸã«å³åŽè³éèããè¡
液ïŒmlãæ¡åããããªãæè¬çŽåã«ãåæ§ã«è¡
液ãæ¡åããå®éšã®å¯Ÿç §ãšãããæ¡è¡ã«èŠãã
æéã¯ãã¹ãŠïŒå以å ã§ãã€ãã ïŒ åè¡æŽ»æ§æž¬å®æ³ LeeâWhiteæ³ã«ããå šè¡ååºæéã枬å®ã
ããããªãã¡ã2.5ml容éã®ãã©ã¹ããã¯è£œæ³š
å°åšïŒä»äž¹ãã«ã¢ç€Ÿè£œïŒã§è³éèããïŒmlã®è¡
液ãæ¡åããçŽã¡ã«ã¹ããããŠãªãããçºå
ããæ¡åããè¡æ¶²ãéããã«å°è©Šéšç®¡ïŒå åŸïŒ
mmãé·ã10cmïŒïŒæ¬ã«ïŒmlãã€å泚ããŠ37âã®
æž©æ°Žäžã«é眮ããæ¡è¡ïŒååŸããïŒæ¬ã®è©Šéšç®¡
ãïŒåæ¯ã«æã«åããŠã¿ãŠããã¯ãæµåããªã
ãªã€ãæç¹ããããïŒæ¬ã®è©Šéšç®¡ãåæ§ã«åã
ãªããåè¡ã芳å¯ãããæ¡è¡ãã第ïŒã®è©Šéšç®¡
ã®åè¡å®äºãŸã§ã®æéãå šè¡ååºæéãšããã ãŠãµã®ã®å šè¡ååºæéã®æ£åžžå€ã¯ãæ£åžžãŠãµ
ã®12å¹ã®æž¬å®å€ã®99ïŒ ãå ¥ãç¯å²ïŒå¹³åå€Â±
3ÏïŒãšãããšã6.5ã12.5åã§ãã€ãã ïŒ çµ æ çµæãå³ïŒã«ç€ºãã å³ïŒããå å ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ãæã
ãŠæäžãããæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³ãæ¬çºæã«ãããã¢ã³ããã
ã³ãã³é«èŠªåæ§ãããªã³ããã³ãããªã³ã«ã«
ã·ãŠã ã¯åœè©²æŽ»æ§ã®æç¶äœçšã«ã€ããŠåäžã®æ
åã瀺ãããšãå€æããã å®éšäŸ ïŒ ïŒ è©Š æ æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³ïŒ3ÎŒïŒmgãJPåäœïŒãæ¬çºæã«ãããã¢
ã³ãããã³ãã³é«èŠªåæ§ãããªã³ïŒ390ÎŒïŒ
mgãJPåäœïŒããã³ãããªã³ã«ã«ã·ãŠã
ïŒ200ÎŒïŒmgãJPåäœïŒãè©Šæãšããã ïŒ å®éšåç© SDç³»éæ§ã©ããïŒS.P.EïŒãäœé230ã280ïœ ïŒ å®éšæ¹æ³ æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ã
ããªã³20ÎŒïŒKgããã³100ÎŒïŒKgãæ¬çºæã«ãã
ãã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³
100ÎŒïŒKgããã³500ÎŒïŒKgããããªã³ã«ã«ã·ãŠ
ã 100ÎŒïŒKgããã³500ÎŒïŒKgãã©ããå°Ÿéèã
ãé泚ãããæè¬æ¶²éããã³æè¬é床ã¯ããã
ã0.1mlïŒ100ïœãçŽ10ç§ïŒ0.1mlã§ããããªã
å¯Ÿç §ãšããŠã¯ïŒïŒ glucose泚å°æ¶²ãæäžããã åºè¡æéã¯Clifftonãã®æ¹æ³ã«æºããŠæž¬å®ã
ããããªãã¡ãã©ããããã©ã¹ããã¯è£œåºå®ç®±
ã«å ¥ãç¡éº»é ç¶æ ã§ãããªã³æäž15ååŸã«å°Ÿã®
å 端ããïŒcmã®éšäœã®å³åŽéèãã¡ã¹ãçšããŠ
åæããçŽãåå£ã«åœãŠè¡æ¶²ãä»çãããåŠ
ãã«ãã€ãŠåºè¡æéã枬å®ããããªãåºè¡ã®æ¿
ããæã¯çŽïŒåæ¯ã«ãããŠæ¢è¡ãããã«ãªã€ãŠ
ããã¯ïŒåæ¯ã«çŽãåå£ã«åœãŠãã ïŒ çµ æ æäž15ååŸã«ãããåºè¡æéã®æž¬å®çµæãè¡š
ïŒã«ç€ºãããªãè¡šïŒã«ã¯ãŠãµã®ã§ã®ãããªã³æ
äž15ååŸã«ãããå šè¡ååºæéã«ã€ããŠã®å®éš
äŸïŒã®å®éšçµæãåèãšããŠä»èšããã
ãè¡šã
è©Šææ¬äžã³ã³ãããŒã«ã¯ïŒïŒ
âã°ã«ã³ãŒã¹ã
Hcã¯ãããªã³ã«ã«ã·ãŠã ãã¯æ¬çºæã«ããã
ã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³ãã¯æ¬çº
æã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ã
æå³ããããŸãåºè¡æéïŒåïŒããã³å šè¡ååºæ
éïŒåïŒã¯ãããããåäŸæ°ã«ãããå¹³åå€Â±95
ïŒ ä¿¡é Œéçããã€ãŠç€ºãã è¡šïŒãã以äžã®äºå®ãå€æããã åäžã®å šè¡ååºæéãäŸãã°å¹³åå€ã§26ã29å
çšåºŠã®å šè¡ååºæéãäžããã«èŠããæäžéãã
ã€ãŠäžè ã®åºè¡æéãæ¯èŒããŠã¿ããšãå¹³åå€ã§
ãããªã³ã«ã«ã·ãŠã ããã³æ¬çºæã«ãããã¢ã³ã
ããã³ãã³é«èŠªåæ§ãããªã³ã¯ãããã75åã
ãã³73åã§ããã«å¯Ÿããæ¬çºæã«ç³»ãã¢ã³ããã
ã³ãã³äœèŠªåæ§ãããªã³ã¯49åã§ãããïŒïŒ â
ã°ã«ã³ãŒã¹æäžïŒã³ã³ãããŒã«ïŒã«ãããåºè¡æ
éã®å¹³åå€ã¯47åã§ãããããæ¬çºæã«ä¿ãã¢ã³
ãããã³ãã³äœèŠªåæ§ãããªã³ãåœè©²éæäžã
ãå Žåã«ã¯ãäºå®äžåºè¡æéã®å»¶é·ã¯èªããããª
ãã ãŸãå å ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ãããŠããã
ãªã³ã«ã«ã·ãŠã ã®æäžé500ÎŒïŒJPåäœïŒïŒKgãæ¬
çºæã«ãããã¢ã³ãããã³ãã³é«èŠªåæ§ãããª
ã³ã®æäžé500ÎŒïŒJPåäœïŒïŒKgããã³æ¬çºæã«ä¿
ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ã®æäžé
100ÎŒïŒJPåäœïŒïŒKgã¯ãåèšå®éšäŸïŒããæšæž¬ã
ãŠã»ãŒåçã§ããããããã®ã¬ãã«ã§ã®æäžéã
ãã€ãŠäžè ã®åºè¡æéãæ¯èŒããŠã¿ããšãå¹³åå€
ã§ãããã168åã191åããã³67åã§ãããæ¬çº
æã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ã
ä»ã®äºã€ã®ãããªã³ã«æ¯èŒããŠãã¯ããã«åºè¡ã®
å±éºæ§ã®å°ãªããã®ã§ããããšãå€æããã æ¥æ§æ¯æ§è©Šéš æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãã
ãªã³ïŒ3ÎŒïŒmgãJPåäœïŒãæ¬çºæã«ãããã¢ã³ã
ããã³ãã³é«èŠªåæ§ãããªã³ïŒ390ÎŒïŒmgãJP
åäœïŒããã³ãããªã³ã«ã«ã·ãŠã ïŒ200ÎŒïŒmgã
JPåäœïŒãè©Šæãšããã äœé23ã27ïœã®ddYç³»éæ§ããŠã¹ã«ããããã
500mgïŒKgã1000mgïŒKgéèæäžãããããã®æ¥
æ§æ¯æ§ã10æ¥éã«ããã€ãŠèŠ³å¯ãããã¢ã³ããã
ã³ãã³é«èŠªåæ§ãããªã³1000mgïŒKg矀ã®ïŒïŒ10
äŸãšãããªã³ã«ã«ã·ãŠã 1000mgïŒKg矀ã®ïŒïŒ10äŸ
ã«ãæäž20ã120ç§åŸã«ãåŸè¢ã®åŒ·çŽæ§çæãçŸ
ãããåŒåžéº»çºã«ããæ»äº¡ãèªããããããã
ããä»ã®æäžçŸ€ã¯10æ¥åŸãŸã§ãã¹ãŠçæ®ããã åŸã€ãŠãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠª
åæ§ãããªã³ã®éèæäžã«ãããLD50ã¯1000
mgïŒKg以äžã§ããã ãªã飌è²æ¡ä»¶ã¯21ã25âã®åç©å®€ã§ãå矀10å¹
ã®ããŠã¹ãïŒã±ãŒãžã«å容ããé€ã¯æ¥æ¬ã¯ã¬ã¢(æ ª)
補åºå飌æCEâïŒãäžããæ°Žã¯çµŠæ°Žãã³ããèª
ç±ã«æåãããã 以äžã«èšèŒããå®æœäŸããã€ãŠæ¬çºæãããã«
詳现ã«èª¬æããã å®æœäŸ ïŒ åžžæ³ã«ããã»ãã¢ããŒãºCLâ4Bãããã ã·ã¢
ã³ã«ãã掻æ§åããããã«ç²Ÿè£œçã¢ã³ãããã³ã
ã³200mgã0.2MâNaHCO3溶液ïŒPH9.0ïŒ200ml
ã«æº¶è§£ãããã®ãå ããŠæžæ¿ãããïŒâã§24æé
ãããæ¹æããéãããããã«0.2Mâ
NaHCO3溶液ïŒPH9.0ïŒ50mlã§ïŒåæŽæ»ããæçµ
çã«ã¯0.2MâNaHCO3溶液ïŒPH9.0ïŒã«æžæ¿ããŠ
æ Œåçµåã¢ã³ãããã³ãã³ã²ã«ãšããã åœè©²æ Œåçµåã¢ã³ãããã³ãã³ã²ã«ãçŽåŸ
2.5cmãé·ã26cmã®ã«ã©ã ã«å å¡«ãã0.05Mâã
ãªã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ãNacl0.15MïŒãå ããŠ
ç·©è¡åãããå¥ã«ãããªã³ã«ã«ã·ãŠã 10mgã
0.05Mâããªã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ãNacl0.15MïŒ
ïŒmlã«ãšãããã«ã©ã ã«è² è·ããã0.05Mâããª
ã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ãNacl0.15MïŒ300mlãæµé
30mlïŒæéã§ééãããäžåååœã10mlã¥ã€ããš
ã€ããåååäžã®ãããªã³ãã«ã«ããŸãŒã«æ³ã«ã
ã€ãŠæ€åºããªãããã¯ãéåžçãããªã³ãæµåºã
ãŠæ¥ãªããªãã®ã確èªãããŸã§ãããªã€ãã éåžçãããªã³ã®ååã®ã¿ãéããè±å¡©ãæ¿çž®
ïŒéå€éæ³ããã€ã€ãããŒUMâïŒã䜿çšïŒãã
æ Œåçµåã¢ã³ãããã³ãã³ã«å床ãããŠæµåºã
ããããæµåºæ¶²ã«ãšã¿ããŒã«ãå ããŠæ²æŸ±ãçã
ãããåããå床溶解ããŠåçµä¹Ÿç¥ããæ¬çºæ
ã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³5.4
mgãåŸãããªããéåžçãããªã³ãæµåºããŠæ¥ãª
ããªãã®ã確èªããåŸã®ã«ã©ã ã«ããã«0.05âã
ãªã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ãNacl1.0MïŒ300mlãæµ
é30mlïŒæéã§ééãããè±å¡©ãæ¿çž®ïŒéå€é
æ³ããã€ã€ãããŒUMâïŒã䜿çšïŒãããšã¿ããŒ
ã«ãå ããŠæ²æŸ±ãçããããåããå床溶解ã
ãŠåçµä¹Ÿç¥ããã¢ã³ãããã³ãã³é«èŠªåæ§ãã
ãªã³4.2mgãåŸãã äžèšã«ã©ã ã¯ãããæäœãïŒåç¹°è¿ããã¢ã³ã
ããã³ãã³äœèŠªåæ§ãããªã³ãç·èš30mgããã³
ã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³ãç·èš22mg
ãåŸãã ããã®ããšãããŠåŸãããã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³25mgãççé£å¡©æ¶²ã«æº¶è§£ããŠ50
ml溶液ãšããç¡èéããŠã¢ã³ãã«å å¡«ããã å®æœäŸ ïŒ å®æœäŸïŒã«ãããŠè£œé èŠæš¡ãæ¡å€§ããç¹ãé€ã
ãŠå®æœäŸïŒèšèŒã®æ¹æ³ãšåæ§ã®æ¹æ³ã«ãã€ãŠã¢ã³
ãããã³ãã³äœèŠªåæ§ãããªã³500mgã補é ã
ãã åœè©²ãããªã³500mgãççé£å¡©æ¶²ã«æº¶è§£ããŠ50
ml溶液ãšããç¡èéããŠãã€ã¢ã¹å å¡«ããã
Hcã¯ãããªã³ã«ã«ã·ãŠã ãã¯æ¬çºæã«ããã
ã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³ãã¯æ¬çº
æã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ã
æå³ããããŸãåºè¡æéïŒåïŒããã³å šè¡ååºæ
éïŒåïŒã¯ãããããåäŸæ°ã«ãããå¹³åå€Â±95
ïŒ ä¿¡é Œéçããã€ãŠç€ºãã è¡šïŒãã以äžã®äºå®ãå€æããã åäžã®å šè¡ååºæéãäŸãã°å¹³åå€ã§26ã29å
çšåºŠã®å šè¡ååºæéãäžããã«èŠããæäžéãã
ã€ãŠäžè ã®åºè¡æéãæ¯èŒããŠã¿ããšãå¹³åå€ã§
ãããªã³ã«ã«ã·ãŠã ããã³æ¬çºæã«ãããã¢ã³ã
ããã³ãã³é«èŠªåæ§ãããªã³ã¯ãããã75åã
ãã³73åã§ããã«å¯Ÿããæ¬çºæã«ç³»ãã¢ã³ããã
ã³ãã³äœèŠªåæ§ãããªã³ã¯49åã§ãããïŒïŒ â
ã°ã«ã³ãŒã¹æäžïŒã³ã³ãããŒã«ïŒã«ãããåºè¡æ
éã®å¹³åå€ã¯47åã§ãããããæ¬çºæã«ä¿ãã¢ã³
ãããã³ãã³äœèŠªåæ§ãããªã³ãåœè©²éæäžã
ãå Žåã«ã¯ãäºå®äžåºè¡æéã®å»¶é·ã¯èªããããª
ãã ãŸãå å ç³»ååºã«å¯Ÿããé»å®³æŽ»æ§ãããŠããã
ãªã³ã«ã«ã·ãŠã ã®æäžé500ÎŒïŒJPåäœïŒïŒKgãæ¬
çºæã«ãããã¢ã³ãããã³ãã³é«èŠªåæ§ãããª
ã³ã®æäžé500ÎŒïŒJPåäœïŒïŒKgããã³æ¬çºæã«ä¿
ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ã®æäžé
100ÎŒïŒJPåäœïŒïŒKgã¯ãåèšå®éšäŸïŒããæšæž¬ã
ãŠã»ãŒåçã§ããããããã®ã¬ãã«ã§ã®æäžéã
ãã€ãŠäžè ã®åºè¡æéãæ¯èŒããŠã¿ããšãå¹³åå€
ã§ãããã168åã191åããã³67åã§ãããæ¬çº
æã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ã
ä»ã®äºã€ã®ãããªã³ã«æ¯èŒããŠãã¯ããã«åºè¡ã®
å±éºæ§ã®å°ãªããã®ã§ããããšãå€æããã æ¥æ§æ¯æ§è©Šéš æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãã
ãªã³ïŒ3ÎŒïŒmgãJPåäœïŒãæ¬çºæã«ãããã¢ã³ã
ããã³ãã³é«èŠªåæ§ãããªã³ïŒ390ÎŒïŒmgãJP
åäœïŒããã³ãããªã³ã«ã«ã·ãŠã ïŒ200ÎŒïŒmgã
JPåäœïŒãè©Šæãšããã äœé23ã27ïœã®ddYç³»éæ§ããŠã¹ã«ããããã
500mgïŒKgã1000mgïŒKgéèæäžãããããã®æ¥
æ§æ¯æ§ã10æ¥éã«ããã€ãŠèŠ³å¯ãããã¢ã³ããã
ã³ãã³é«èŠªåæ§ãããªã³1000mgïŒKg矀ã®ïŒïŒ10
äŸãšãããªã³ã«ã«ã·ãŠã 1000mgïŒKg矀ã®ïŒïŒ10äŸ
ã«ãæäž20ã120ç§åŸã«ãåŸè¢ã®åŒ·çŽæ§çæãçŸ
ãããåŒåžéº»çºã«ããæ»äº¡ãèªããããããã
ããä»ã®æäžçŸ€ã¯10æ¥åŸãŸã§ãã¹ãŠçæ®ããã åŸã€ãŠãæ¬çºæã«ä¿ãã¢ã³ãããã³ãã³äœèŠª
åæ§ãããªã³ã®éèæäžã«ãããLD50ã¯1000
mgïŒKg以äžã§ããã ãªã飌è²æ¡ä»¶ã¯21ã25âã®åç©å®€ã§ãå矀10å¹
ã®ããŠã¹ãïŒã±ãŒãžã«å容ããé€ã¯æ¥æ¬ã¯ã¬ã¢(æ ª)
補åºå飌æCEâïŒãäžããæ°Žã¯çµŠæ°Žãã³ããèª
ç±ã«æåãããã 以äžã«èšèŒããå®æœäŸããã€ãŠæ¬çºæãããã«
詳现ã«èª¬æããã å®æœäŸ ïŒ åžžæ³ã«ããã»ãã¢ããŒãºCLâ4Bãããã ã·ã¢
ã³ã«ãã掻æ§åããããã«ç²Ÿè£œçã¢ã³ãããã³ã
ã³200mgã0.2MâNaHCO3溶液ïŒPH9.0ïŒ200ml
ã«æº¶è§£ãããã®ãå ããŠæžæ¿ãããïŒâã§24æé
ãããæ¹æããéãããããã«0.2Mâ
NaHCO3溶液ïŒPH9.0ïŒ50mlã§ïŒåæŽæ»ããæçµ
çã«ã¯0.2MâNaHCO3溶液ïŒPH9.0ïŒã«æžæ¿ããŠ
æ Œåçµåã¢ã³ãããã³ãã³ã²ã«ãšããã åœè©²æ Œåçµåã¢ã³ãããã³ãã³ã²ã«ãçŽåŸ
2.5cmãé·ã26cmã®ã«ã©ã ã«å å¡«ãã0.05Mâã
ãªã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ãNacl0.15MïŒãå ããŠ
ç·©è¡åãããå¥ã«ãããªã³ã«ã«ã·ãŠã 10mgã
0.05Mâããªã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ãNacl0.15MïŒ
ïŒmlã«ãšãããã«ã©ã ã«è² è·ããã0.05Mâããª
ã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ãNacl0.15MïŒ300mlãæµé
30mlïŒæéã§ééãããäžåååœã10mlã¥ã€ããš
ã€ããåååäžã®ãããªã³ãã«ã«ããŸãŒã«æ³ã«ã
ã€ãŠæ€åºããªãããã¯ãéåžçãããªã³ãæµåºã
ãŠæ¥ãªããªãã®ã確èªãããŸã§ãããªã€ãã éåžçãããªã³ã®ååã®ã¿ãéããè±å¡©ãæ¿çž®
ïŒéå€éæ³ããã€ã€ãããŒUMâïŒã䜿çšïŒãã
æ Œåçµåã¢ã³ãããã³ãã³ã«å床ãããŠæµåºã
ããããæµåºæ¶²ã«ãšã¿ããŒã«ãå ããŠæ²æŸ±ãçã
ãããåããå床溶解ããŠåçµä¹Ÿç¥ããæ¬çºæ
ã«ä¿ãã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³5.4
mgãåŸãããªããéåžçãããªã³ãæµåºããŠæ¥ãª
ããªãã®ã確èªããåŸã®ã«ã©ã ã«ããã«0.05âã
ãªã¹å¡©é žç·©è¡æ¶²ïŒPH7.5ãNacl1.0MïŒ300mlãæµ
é30mlïŒæéã§ééãããè±å¡©ãæ¿çž®ïŒéå€é
æ³ããã€ã€ãããŒUMâïŒã䜿çšïŒãããšã¿ããŒ
ã«ãå ããŠæ²æŸ±ãçããããåããå床溶解ã
ãŠåçµä¹Ÿç¥ããã¢ã³ãããã³ãã³é«èŠªåæ§ãã
ãªã³4.2mgãåŸãã äžèšã«ã©ã ã¯ãããæäœãïŒåç¹°è¿ããã¢ã³ã
ããã³ãã³äœèŠªåæ§ãããªã³ãç·èš30mgããã³
ã¢ã³ãããã³ãã³é«èŠªåæ§ãããªã³ãç·èš22mg
ãåŸãã ããã®ããšãããŠåŸãããã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³25mgãççé£å¡©æ¶²ã«æº¶è§£ããŠ50
ml溶液ãšããç¡èéããŠã¢ã³ãã«å å¡«ããã å®æœäŸ ïŒ å®æœäŸïŒã«ãããŠè£œé èŠæš¡ãæ¡å€§ããç¹ãé€ã
ãŠå®æœäŸïŒèšèŒã®æ¹æ³ãšåæ§ã®æ¹æ³ã«ãã€ãŠã¢ã³
ãããã³ãã³äœèŠªåæ§ãããªã³500mgã補é ã
ãã åœè©²ãããªã³500mgãççé£å¡©æ¶²ã«æº¶è§£ããŠ50
ml溶液ãšããç¡èéããŠãã€ã¢ã¹å å¡«ããã
å³ïŒã¯å®éšäŸïŒã®ïŒçµæã®é
ã«èšèŒã®å³ïŒã«çž
åœãããããªã³æäžããäžå®æéåŸã«ãããå šè¡
ååºæéïŒïŒäŸå¹³åïŒã®å€åã瀺ãã°ã©ãã§ã
ãããªãâ å°ç·ã¯æ¬çºæã«ãããã¢ã³ãããã³ã
ã³é«èŠªåæ§ãããªã³100ÎŒïŒKgãéèæäžãã
å Žåãâå°ç·ã¯æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³20ÎŒïŒKgãéèæäžããå Žåã
ãã³â²å°ç·ã¯ãããªã³ã«ã«ã·ãŠã 100ÎŒïŒKgãé
èæäžããå Žåã«ãããããããã®å€åã瀺ãã
åœãããããªã³æäžããäžå®æéåŸã«ãããå šè¡
ååºæéïŒïŒäŸå¹³åïŒã®å€åã瀺ãã°ã©ãã§ã
ãããªãâ å°ç·ã¯æ¬çºæã«ãããã¢ã³ãããã³ã
ã³é«èŠªåæ§ãããªã³100ÎŒïŒKgãéèæäžãã
å Žåãâå°ç·ã¯æ¬çºæã«ä¿ãã¢ã³ãããã³ãã³
äœèŠªåæ§ãããªã³20ÎŒïŒKgãéèæäžããå Žåã
ãã³â²å°ç·ã¯ãããªã³ã«ã«ã·ãŠã 100ÎŒïŒKgãé
èæäžããå Žåã«ãããããããã®å€åã瀺ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ãæå¹
æåãšããŠå«æããæè¡æ¶²ååºå€ã ïŒ ã¢ã³ãããã³ãã³äœèŠªåæ§ãããªã³ãçç
çPHããã³çççå¡©æ¿åºŠã«ãããŠæ Œåçµåã¢ã³ã
ããã³ãã³ã«åžçããªããããªã³ã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æè¡æ¶²ååºå€ã ïŒ çççPHãPHïŒãïŒã®ç¯å²ã«ããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®æè¡æ¶²ååºå€ã ïŒ çççå¡©æ¿åºŠãå¡©åãããªãŠã æ¿åºŠ0.05ã
0.20Mã®ç¯å²ã«ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ããã³
第ïŒé èšèŒã®æè¡æ¶²ååºå€ã ïŒ æ Œåãã»ãã¢ããŒãº4Bã§ããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé ã第ïŒé ããã³ç¬¬ïŒé èšèŒã®æè¡æ¶²ååº
å€ã
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56017994A JPS57134419A (en) | 1981-02-12 | 1981-02-12 | Stable anticoagulant of blood |
| US06/345,834 US4415559A (en) | 1981-02-12 | 1982-02-04 | Anticoagulant |
| EP82101017A EP0058397A3 (en) | 1981-02-12 | 1982-02-11 | Anticoagulant and the use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56017994A JPS57134419A (en) | 1981-02-12 | 1981-02-12 | Stable anticoagulant of blood |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57134419A JPS57134419A (en) | 1982-08-19 |
| JPS6353970B2 true JPS6353970B2 (ja) | 1988-10-26 |
Family
ID=11959270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56017994A Granted JPS57134419A (en) | 1981-02-12 | 1981-02-12 | Stable anticoagulant of blood |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4415559A (ja) |
| EP (1) | EP0058397A3 (ja) |
| JP (1) | JPS57134419A (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745106A (en) * | 1986-08-20 | 1988-05-17 | Griffin Charles C | Heparin derivatives having improved anti-Xa specificity |
| US4942156A (en) * | 1986-08-20 | 1990-07-17 | Hepar Industries, Inc. | Low molecular weight heparin derivatives having improved anti-Xa specificity |
| IT1237518B (it) * | 1989-11-24 | 1993-06-08 | Renato Conti | Eparine supersolfatate |
| SE9003181D0 (sv) * | 1990-10-04 | 1990-10-04 | Kabivitrum Ab | Use of heparin fraction |
| WO1993006836A1 (en) * | 1991-10-04 | 1993-04-15 | Virginia Commonwealth University | Von willebrand factor-specific heparin fractions |
| WO1994022471A1 (en) * | 1993-04-05 | 1994-10-13 | The Green Cross Corporation | Liquid antithrombin iii preparation and method of stabilizing the same |
| DE19538716A1 (de) * | 1995-10-18 | 1997-04-24 | Behringwerke Ag | Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa) |
| DE19538715A1 (de) | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| WO1999010746A2 (en) * | 1997-08-26 | 1999-03-04 | The University Of North Carolina At Chapel Hill | Method of monitoring blood low molecular weight heparin and heparin |
| US20070166344A1 (en) * | 2006-01-18 | 2007-07-19 | Xin Qu | Non-leaching surface-active film compositions for microbial adhesion prevention |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4119774A (en) * | 1976-03-05 | 1978-10-10 | Ab Kabi | Heparin purification method |
| US4301153A (en) * | 1977-03-21 | 1981-11-17 | Riker Laboratories, Inc. | Heparin preparation |
| US4122250A (en) * | 1977-08-22 | 1978-10-24 | Gottfried Schmer | Separation of high-activity heparin by affinity chromatography |
| US4175182A (en) * | 1978-07-03 | 1979-11-20 | Research Corporation | Separation of high-activity heparin by affinity chromatography on supported protamine |
| FR2461719A2 (fr) * | 1979-07-20 | 1981-02-06 | Choay Sa | Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir |
| GB2051103A (en) * | 1979-04-11 | 1981-01-14 | Choay Sa | Heparin fractions |
| IL61201A (en) * | 1979-10-05 | 1984-09-30 | Choay Sa | Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them |
-
1981
- 1981-02-12 JP JP56017994A patent/JPS57134419A/ja active Granted
-
1982
- 1982-02-04 US US06/345,834 patent/US4415559A/en not_active Expired - Fee Related
- 1982-02-11 EP EP82101017A patent/EP0058397A3/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0058397A3 (en) | 1984-01-04 |
| JPS57134419A (en) | 1982-08-19 |
| EP0058397A2 (en) | 1982-08-25 |
| US4415559A (en) | 1983-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Zwaan et al. | Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction | |
| Milani Júnior et al. | Snake bites by the jararacuçu (Bothrops jararacussu): clinicopathological studies of 29 proven cases in São Paulo State, Brazil. | |
| Wardrop et al. | The story of the discovery of heparin and warfarin | |
| US6624141B1 (en) | Protamine fragment compositions and methods of use | |
| JP7301741B2 (ja) | è£äœæŽ»æ§ã®ã¢ãžã¥ã¬ãŒã¿ | |
| Diamond et al. | Nonanticoagulant protective effect of heparin in chronic aminonucleoside nephrosis | |
| WO1983000016A1 (en) | METHOD OF TREATING A PATIENT USING HEMOSTATIC AGENT FACTOR VIIa, COMPOSITION THEREFOR, AND METHOD OF PREPARING SAME | |
| EP0406398A1 (en) | COMPOSITIONS AND METHOD FOR TREATING OR PROPHYLAXIS OF SEPSIS OR SEPTIC SHOCK. | |
| Jorpes | The origin and the physiology of heparin: the specific therapy in thrombosis | |
| BG61231B1 (en) | A method for isolating factor viii | |
| RU2426745C2 (ru) | РекПЌбОМаМÑÐœÑй Ñ ÐžÐŒÐµÑÐœÑй белПк ÑакÑПÑа ОМгОбОÑÐŸÐ²Ð°ÐœÐžÑ ÐœÐµÐ¹ÑÑПÑОлПв О гОÑÑгеМа О ÑПЎеÑжаÑÐ°Ñ ÐµÐ³ÐŸ ÑаÑЌаÑевÑОÑеÑÐºÐ°Ñ ÐºÐŸÐŒÐ¿ÐŸÐ·ÐžÑÐžÑ | |
| JPS6353970B2 (ja) | ||
| KR20140135219A (ko) | ìê°ì ìŠì ì¹ë£ììì ìí°ížë¡¬ë¹ì ì©ë | |
| Wessler et al. | A distinction between the role of precursor and activated forms of clotting factors in the genesis of stasis thrombi | |
| JP2758162B2 (ja) | åºè¡çŸæ£ã®æ²»çæ¹æ³ããã³æ²»ççšçµæç© | |
| Raife et al. | Lepirudin prevents lethal effects of Shiga toxin in a canine model | |
| EP3746151B1 (en) | Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof | |
| JPS62255430A (ja) | åºä¹³åç©ã®è管ç ãæ²»çããæ¹æ³ | |
| Fahey et al. | Effect of dicumarol on Ac-globulin and prothrombin activity. | |
| RU2456993C1 (ru) | ÐПЌпПзОÑÐžÑ ÐœÐ° ПÑМПве вÑÑПкПЌПлекÑлÑÑМПгП гепаÑОМа Ñ Ð°ÐœÑОкПагÑлÑÐœÑÐœÑЌО, аМÑОÑÑПЌбПÑОÑаÑÐœÑЌО, ÑОбÑОМПлОÑОÑеÑкОЌО О ÑОбÑОМЎепПлОЌеÑОзаÑОПММÑЌО ÑвПйÑÑваЌО | |
| JP6059578B2 (ja) | ãã³ã€ãã³ãå«æããæ¢è¡ä¿é²å€ | |
| Brown et al. | Anticoagulants and anticoagulant therapy: a review | |
| CN102178929B (zh) | ç¬é©è«æåèœåå ¶çªåäœåšå¶å€æº¶è¡æ è¯ç©äžççšé | |
| Rosenthal | Experimental studies on acute mercurial poisoning | |
| RU2058788C1 (ru) | СпПÑПб пПлÑÑÐµÐœÐžÑ Ð¿ÑепаÑаÑа ОМÑÑлОМа ÐŽÐ»Ñ Ð¿ÐµÑПÑалÑМПгП пÑÐžÐŒÐµÐœÐµÐœÐžÑ |